IMMOLIBILIZED OLIGONUCLEOTIDE PROBES AND USES THEREOF.

Priority: 10.03.89 US 321728

Date of publication of application: 02.01.92 Bulletin 92/01

Publication of the grant of the patent: 22.02.95 Bulletin 95/08

Designated Contracting States:
AT BE CH DE DK ES FR GB IT LI LU NL SE

References cited:
EP-A- 0 139 489
EP-A- 0 305 145
WO-A-87/03911
US-A- 4 751 177

Dialog Information Services, File 154, Medline 83-90, Dialog accession no. 89364863, Morrissey D.V. et al.

Proprietor: AMOCO CORPORATION
200 East Randolph Drive
P.O. Box 87703
Chicago
Illinois 60680-0703 (US)

Inventor: COLLINS, Mark, L.
435 Malden Street
Holden, MA 01520 (US)
Inventor: MORRISSEY, David, V.
234 South Main Street
Unit 312
Middletown, CT 06457 (US)

Representative: Holdcroft, James Gerald, Dr.
et al
Graham Watt & Co.,
Riverhead
Sevenoaks, Kent TN13 2BN (GB)

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).
Description

Background

Biological samples generally contain nucleic acid sequences which encode information unique to its biological source. For example, all species of bacteria which belong to a certain genus (e.g., Campylobacter or Enterobacter) share certain physical characteristics which are encoded by the same nucleotide sequences present in most or all of the species within the genus. Thus, an assay which is specific for the genus can be based upon these common nucleotide sequences.

Detection of nucleotide sequences in a sample can be carried out using nucleotide probes specific for these target sequences. For example, Nagata et al., FEBS, 183:379-382 (1985), describe the use of UV irradiation to bind heterologous high molecular weight DNA to polystyrene microtiter wells in order to detect specific sequences within the immobilized DNA by way of specific DNA probes.

Zouali and Stollar, J. Immuno. Methods, 90:105-110 (1986), describe a technique for the attachment of high molecular weight nucleic acids to polystyrene microtiter wells using pre-treatment of the support with UV irradiation.

Polsky-Cynkin et al., Clinical Chemistry, 31:1438-1443 (1985), describe the use of immobilized capture probes in clinical assays.


Stabinsky, U.S. Patent Number 4,751,177, describes a single-step target capture that utilizes a hybridization of a tailed capture probe in solution followed by a solid phase capture with oligo-(dT)-controlled pore glass.

Soderlund, UK Patent Application GB 2169403A (1985), describes several affinity-based capture hybridization methods which use two probes, detector probe and a capture probe that contains one member of an affinity pair.

Collins, European Patent Application Number 265 244, describes a nonisotopic reversible target capture protocol which makes use of dA-tailed oligonucleotide probes and oligo(dT)-magnetic particles and poly(dT) filters.

Presently available nonisotopic assay methods are either lacking in sensitivity for certain applications, or are too complex or too slow to be clinically useful. They also require a sample to be split in order to perform multiple assays thereon, resulting in decreased sensitivity. Most of the prior art methods also employ solid phases that are not easily separated from viscous clinical samples, such as stool. It would be helpful to have a rapid, nonisotopic assay useful for assaying complex or unpurified samples that is highly specific, simple to use useful with RNA as well as DNA targets and applicable to clinical and food samples with no prior purification of the nucleic acids of the samples.

Summary of the Invention

The present invention pertains to a method of isolating or determining the presence or amount of a target nucleic acid in a sample, the method being of the type which involves the use of (i) an immobilizable capture probe comprising a tail and a target binding region which is a mixed base oligonucleotide sequence complementary to the target nucleic acid sequence and (ii) a substratum which is affixed to a solid support, the tail and the substratum together forming an affinity pair, characterized in that said method comprises the steps of:

(a) providing a polynucleotide substratum comprising a (dT) or (dA) homopolymer or the polymer of a simple repeating nucleotide sequence of (dT) and (dA), for example (dT)_n, (dA)_n, (dAdT)_n or (dAdAdTdT)_n, where n is sufficiently large to refer to a polymer of from about 50 to about 3000 nucleotides affixed to a solid polymeric support;

(b) contacting, under hybridizing conditions, the polynucleotide substratum with a capture probe consisting essentially of a target binding region and a tail which is an oligonucleotide or a polynucleotide, the sequence of which is complementary to the polynucleotide substratum, such that a first hybridized region is formed between the tail and the polynucleotide substratum to obtain a preimmobilized capture probe; and

(c) contacting the sample with the preimmobilized capture probe under hybridizing conditions, such that if the target nucleic acid is present in the sample, a second hybridized region is formed between the target nucleotide sequence and the target binding region of the capture probe to obtain an immobilized
target nucleic acid. The method is simple and rapid and does not require the use of radioactive materials. In the method of the present invention, oligonucleotide probes (capture probes), which are specific for nucleic acids to be detected (target nucleic acids), and bound to an appropriate support, are contacted with a sample to be analyzed for the target nucleic acids, under conditions appropriate for hybridization of complementary nucleic acid sequences to occur. In general, the sample has been previously treated in such a manner that the molecular structure of the cells is disrupted (i.e., the cell structure, such as the chromosomes and membranes are broken, and the cellular cytoplasm is dispersed).

In the method of the present invention, a sample is treated to release the nucleic acids of cells contained in the sample, and is combined with a capture probe, which is reversibly attached or preimmobilized on a support, such as polystyrene, by means of a homopolymer tail whose sequence is complementary to a sequence present on the support surface. Hybridization of complementary nucleic acid sequences results in capture of target nucleic acids from the sample. Capture of the target on the solid supports also serves to separate the target nucleic acids from sample impurities prior to nonisotopic or radioisotopic detection. Target nucleic acids can be detected and/or quantified by hybridizing the captured target with a labeled probe, for example.

The present method has numerous advantages over presently-available methods. For example, the present method makes it possible to: (1) analyze many samples (e.g., 20 or more) nonisotopically in a short time; (2) carry out analyses without sample filtration or cell culture or prior purification of nucleic acids; (3) run a panel of tests on a sample simultaneously without crosstalk; (4) run multiple tests on a small volume sample; and (5) use capture probes without prior purification. In addition, the method can be efficiently performed using a single labeled probe, since one generic probe can be constructed (e.g., by cloning) to hybridize to all target nucleic acids that make up a screen or a panel. The present assay method allows the non-radioactive detection of as little as one hundred attomoles of target nucleic acid in any type of cell extract (bacterial, mammalian, yeast, plant), in food and clinical samples and other impure biological specimens in about two hours.

In addition to its use in detecting and/or quantitating the level of target present in a sample, the present invention can also be used, without the customary phenol extraction, to isolate nucleic acid targets from crude specimens for cloning (or subcloning) and/or amplification. Substantial purification of the target prior to either cloning or target amplification (such as the PCR method, Mullis, U.S. Patent 4,683,202) reduces the level of background (and thus improves the specificity) of these procedures as well as removing numerous interfering substances present in crude specimens. In addition, if necessary, the sensitivity of the detection of targets by the present method can be substantially improved by inserting an optional target amplification method between target capture and detection or by using reversible target capture methods as disclosed herein.

The method of the present invention is particularly useful for precious or small volume samples because it is not necessary to divide the sample into smaller samples for each test to be carried out. Another advantage of the present invention is that a nonspecific or generic reporter probe can be used because the possible loss of signal due to the presence of interfering substances or high levels of competitor organisms is avoided by capturing target nucleic acid sequences from the sample being tested prior to labeling.

The present invention also includes kits for rapid analysis of samples by the method of the present invention. A kit can contain, for example, suitable solid supports, such as dipsticks or wells, which contain a substratum, which is discussed in greater detail hereinbelow, and a specific capture probe prehybridized to the substratum, and an agent, such as a lysis solution, for disrupting cells to free cellular nucleic acids for detection. Alternatively, the kit can contain capture probes which are not bound to the solid phase. This requires the user to perform the prehybridization step. Such a system allows the user more flexibility since the user would prepare the appropriate capture probe-solid phase adducts whenever desired. The kit can, optionally, contain a labeled probe and a means for detecting the labeled probes, positive and/or negative control samples, elution buffers for carrying out reversible target capture and amplification or cloning reagents.

Brief Description of the Figures

Figure 1 depicts the rate of capture of rRNA targets with (A) the capture probe free in solution; or (B) with the capture probe prehybridized to the polystyrene.

Figure 2 depicts the dose-response curve for the nonisotopic detection of Salmonella typhimurium in 25% w/v normal stool with the present invention.
Figure 3 is a schematic representation of the nucleotide sequence of the oligonucleotide probes used in the present invention.

Detailed Description of the Invention

The present invention relates to a rapid, nonisotopic method of determining (detecting and/or quantitating) nucleic acid sequences of interest (target nucleic acid sequences) in a sample, as well as a method of isolating or purifying target nucleic acid sequences (e.g., for the purpose of amplification or cloning), materials useful in carrying out the method and kits containing such materials, useful for determining target nucleic acid sequences in a sample.

In the method of the present invention, a complex sample to be analyzed for the presence of one or more of the target nucleic acid sequences is combined with a solid support which has affixed to or immobilized on its surface nucleic acid sequences, or probes, referred to as "capture nucleic acid sequences" or "capture probes". The capture probes are complementary to the target nucleic acid sequences, and, under appropriate conditions, will hybridize with the target nucleic acid sequences.

The capture probes are bound to a polynucleotide layer or substratum, which is discussed in greater detail below, which is coated directly on the solid support, through a "tail" which is complementary to the substratum.

The present method can be used on any sample which contains nucleic acids. The sample must be sufficiently liquid to allow contact with the probe and for hybridization to occur. The sample can be complex, clinical samples, such as, mucus, sputum, urine, stool, or blood, or foods or beverage, such as milk, cheese, wine or prepared foods. The sample does not have to be separated, filtered or precultured prior to use of the present method. The sample is generally pretreated with an agent which disrupts molecular structures within the cells. These agents are referred to as "agents that disrupt molecular structures" (e.g., "chaotropic agents"), and will disrupt the cells, or viruses, present in the sample to release nucleic acids. Such agents are generally compounds or solvents which disrupt the molecular structure of a cell, that is, these agents are capable of denaturing the secondary, tertiary and/or quaternary structures of biopolymers, including proteins, nucleic acids and polysaccharides, that are generally found in specimens. Examples of agents that disrupt molecular structures are chaotropic salts (e.g., guanidinium thiocyanate), and non-ionic salts of large acidic anions (e.g., triflic acid, trifluoroacetic acid), denaturing detergents (e.g., dodecyl sulfate), hydrolytic enzymes (e.g., proteases), and compounds which disrupt hydrophobic bonds (e.g., phenols, dimethyl formamide, dimethylsulfoxide, tetramethyl urea, guanidinium hydrochloride) or hydrogen bonds (e.g., urea, formamide). Physical or mechanical means of disrupting molecular structures, e.g., sonication, can also be used to release nucleic acids. Agents that disrupt molecular structures can be used singly or in various combinations to achieve a desired result.

Solid supports which can be used in the present invention include any solid material to which can be bound sufficient amounts of the substratum polynucleotide to allow the capture probe to be pre-hybridized to the support. Polymeric materials, such as agarose beads or polystyrene, are generally useful as supports.

Polystyrene is a particularly useful support for use in the present invention because it can bind large amounts of polynucleotide substratum material, allows facile nonisotopic detection of targets, and has relatively low nonspecific binding of both enzymes and nucleic acids. By "nonspecific binding" is meant the target-independent binding of a probe to a solid support. The forces responsible for the sticking are not well understood (hence the use of the word "nonspecific"), but van der Waals bonds, hydrophobic bonds, and hydrogen bonds are thought to be likely contributors to the total energy of the binding. The labeled probe may be uncomplexed but more likely is complexed with one or more cellular components that enhance the tendency of the probe to bind to the solid support. It is measured by incubating the sample or specimen, the labeled probe, the capture probe, and solid support in the absence of the target, and in the absence of any "pseudo targets" (i.e., targets closely resembling the actual target) with which nonspecific hybrids may form. The configuration of the support will vary depending upon the type of assay and the nature of the samples to be assayed. Configurations such as microtiter wells, tubes and dipsticks are useful in the present invention and allow the simultaneous assay of a large number of samples to be performed manually in an efficient and convenient way. The assay can also be automated using, for example, microtiter wells and is capable of extensive automation because of automatic pipetters and plate readers. Other solid phases, particularly other plastic solid supports, may also meet these basic criteria (including the ability to adsorb large amounts of polynucleotide) and thus be suitable for use in the present invention.

A substratum or layer is coated onto the supports. The "substratum" is a layer of material that is laid down on a solid support by covalent or noncovalent means, which greatly enhances the binding of the next
layer of material. The substratum is a polynucleotide from about 50 to about 3000, or more, nucleotides in length. About 1500 to 3000 nucleotide bases is a particularly useful length. The substrate materials are homopolynucleotides of deoxyribothymidylate (dT) and deoxyriboadenylate (dA). Poly(dT) and poly(dA) are particularly preferred substrata for the present invention. However, mixed sequences comprising simple repeating polynucleotide sequences, having repeat sequences no longer than about a tetranucleotide, can be used. For example, alternating nucleotides (e.g., GTGT or GGTTGTT) can be used as the substratum, wherein the length of each repeat sequence is four nucleotides or less. In general, about 250 ng to about 1 μg of substratum is bound to the support.

Binding a substratum or layer of material to a solid support (such as polystyrene) allows the binding of a multiplicity of oligonucleotide capture probes (up to about 1 μg), which in the absence of the substratum do not bind to the solid support (< 1 ng to polystyrene). More than one substratum layer can be bound to a support. For example, large adaptor molecules containing short tails, as well as a multiplicity of properly spaced secondary ligands, can be bound to a poly(dT) (or other polynucleotide) substratum bound to polystyrene. The multiplicity of secondary ligands constitute the second layer or second substratum. Thus many first probes or other adaptor molecules can bind to the solid support and each of them would be capable of binding a plurality of capture probes. Additional layers can be added as needed. In this way the capacity of the solid support can be increased to any desired level to improve the speed and efficiency of the capture of target molecules.

The capture probes are mixed base nucleic acid sequences, which are specific for the target nucleic acids to be detected. The mixed base sequences of the probe allows it to base-pair only with the complementary sequence of the target nucleic acid, under appropriate conditions of stringency. That is, the capture probe may bind "pseudo targets" which have sequences which are closely, but not exactly complementary to the mixed base sequence of the probe, forming nonspecific hybrids. Nonspecific hybridization can be reduced under stringency conditions. (Stringency is described below, and in detail in Example 6). The specific sequence of the capture probe will depend upon, and be complementary to, the nucleic acid sequence of the target nucleic acid. The probe can be DNA or RNA.

The capture probes are bound, via a "tail", to the substratum present on a solid support. The tail is an RNA or DNA sequence that is complementary to the substratum. The tail can be added either synthetically or enzymatically to either the 5' or 3' end, or middle, of the capture probe. Thus, if the substratum is poly(dT), a complementary tail would consist of poly(dA). Oligonucleotides (i.e., about 10-50 nucleotides) are preferred as capture probes over polynucleotides (i.e., more than about 50 nucleotides) because of the former's greater specificity. Oligonucleotides can readily distinguish a perfectly formed double helix (exact match) from just a single-base pair mismatch. This exceptional specificity has been termed "allele specificity", Connor, B.J. et al. (1983), Proc. Natl. Acad. Sci. USA, 80, 278-282 describe the allele-specificity of oligonucleotides generally. Collins and Hunsaker, (1985), Anal. Biochem., 151, 211-224 describe the allele-specificity of tailed oligonucleotides.

The tailed capture probe is reversibly or noncovalently bound to the substratum. That is, the binding of the tail to the substratum can be changed by a simple physical stress, such as increasing the temperature or the chaotrope concentration. Thus, capture probes bound to a poly(dT) substratum via a (dA) tail can be readily removed, after binding with the target nucleic acid for further processing. This can be done for example, simply by adding heated buffer to the polystyrene or increasing the concentration of a chaotrope or nucleic acid denaturant above a certain threshold level. The probe-target complex can be recaptured by cooling, or by a simple dilution of the nucleic acid denaturant.

In one embodiment of the present invention, UV or gamma radiation is used to bind the homopolynucleotide substratum, such as poly(dT), to solid supports, such as micrometer wells, dipsticks, and tubes. The process of binding a polynucleotide substratum to a substrate is described in detail in Example 1.

The tailed capture probe is immobilized on the substratum by prehybridizing the probe with the substratum. That is, the tailed probe is hybridized to the substratum complementary sequence prior to use in an assay. In the preferred method, the substratum sequence is poly(dT) and the tail is poly(dA). However, other simple repeating sequences can be substituted for the dA-dT affinity pair. The repeating sequences should preferably be no longer than about a tetranucleotide (i.e., 4 nucleotide bases) in order to provide the rapid hybridization kinetics that would be desirable in a manufacturing process. In prior art methods, the tailed probe is added by the user to the specimen, and bound to the target in solution and then bound to the solid support. That format is disadvantageous in that multiple tests cannot be performed on each sample, and the tail on the capture probe must be long to overcome steric hindrance in the approach of the target to the support. In the present method, the user simply combines one or more solid supports, already containing bound capture probes, and the sample and maintains the resulting combination under conditions
appropriate for hybridization of complementary sequences to occur.

More than one type of immobilized oligonucleotide capture probe can be contacted with a single sample at one time, thus making it possible to analyze the sample for more than one target nucleic acid sequence at a time. For example, different solid supports specific for different bacterial genera can be used simultaneously to test one sample for the presence of the bacteria. The stability of the linkage between the probes and the substrate substantially prevents cross-hybridization, or "cross-talk", among the different types of probes. The term "cross-talk" means interprobe exchange of capture and or target oligonucleotides. That is, where one or more dipstick probes is contacted with a sample, a capture oligonucleotide bound to one of the dipsticks, which may or may not be hybridized with a target nucleic acid, detaches from the dipstick and becomes bound to another dipstick in the sample. This migration of probes between dipsticks is "cross-talk". The term can apply to other support configurations besides dipsticks, which was used merely to illustrate the present example.

Prehybridizing the capture probe to the support eliminates the need to purify the capture probes after the tailing reaction. Only oligonucleotides with a tail of sufficient length will bind to the coated polystyrene.

Prehybridization also helps to overcome potential interference from endogenous poly(A) or poly(dA), which interference is potentially significant in clinical samples containing a large number of human cells. Capture probes with very short tails can be used since the target cannot sterically hinder the tail's attempt to bind to the solid support. The tail length need only be sufficiently long to form stable hybrids with poly-(dT) in the buffer employed. Reduced tail length also decreases the cost of the capture probes. The preferred tail length is from about 15 to about 30 nucleotides.

In the method of the present invention, oligonucleotide capture probes preimmobilized on solid supports by way of the homonucleotide affinity pair are contacted with the sample for direct detection of specific microorganisms in the samples. For example, Campylobacter has been detected directly in clinical stool samples with about 90% specificity and sensitivity. The assay can detect Campylobacter and Salmonella seeded in 25% w/v normal stool at less than $1.0 \times 10^5$ cells/ml.

The method described herein simplifies sample handling and processing in that filtration normally required for stool and other viscous or chunky samples is omitted and pipetting can be minimized due to the ability to add one dipstick for each test to every sample. The preimmobilization of the capture probe on a solid support allows simultaneous analysis of each and every clinical sample for a number of different analytes.

In the present method, specimens are first dissolved by a chaotropic agent (e.g., a solvent disrupting molecular structures). By doing capture in a chaotropic solvent which disrupts the molecular structures of the target cells or viruses prior to labeling, other substances that could potentially interfere with this nonisotopic assay, such as endogenous biotin, avidin, avidin-like molecules, nucleases, proteases, and nucleic acid binding proteins, are removed prior to the introduction of the labeled generic probe. A number of immobilized capture probes, for example, polystyrene dipsticks, each with a different specific capture probe (including an optional nonsense control sequence), is then placed into each sample to remove target molecules complementary to each of the target probes. The dipsticks are removed from the specimens, washed, labeled, for example, with a generic reporter probe, and detected nonisotopically. Nonisotopic detection can be carried out using the biotin-streptavidin-alkaline phosphatase system described by Leary et al. in Proc. Nat'l. Acad. Sci. USA, 80:4045-4049 (1983). The targets can also be labeled with labels such as fluorophores, chemiluminescent compounds or radioisotopes and detected using standard methods.

The present method optionally includes a "stringency" wash step. A stringency wash is a wash protocol that reduces nonspecific hybridization. A nonspecific hybrid is an imperfect hybrid, that is, one that contains mostly correct base pairs, but has one or more mismatched bases (e.g., A not paired with T or U; C not paired with G). Nonspecific hybrids generally have a lower dissociation temperature than the perfectly base-paired hybrid between the actual target and the capture probe. Nonspecific hybridization results in a complex of a capture probe and a "pseudo-target", which is a molecule that closely resembles the actual or real target in its base sequence. The temperature of a stringency wash is generally about 1-5°C below the dissociation temperature of the capture probe-target complex, but just above the dissociation temperature of any capture probe-pseudo target complexes that may be present. A quaternary salt, such as tetraethylammonium chloride (TEA C1) can be used for the stringency wash. For example, at a concentration of 2.4M, TEA C1 confers equivalence to G-C and A-T base pairing, allowing the stringency of hybridization to be controlled at a single temperature (for a fixed probe length) in a manner that is completely independent of GC content. Wood, W.I., et al., (1985), Proc. Natl. Acad. Sci, 82:1585-1588. Since TEA C1 strengthens A-T base pairing in relation to G-C, it was employed as a wash reagent to maintain tight binding of the dA-tailed probe to the poly (dT) coated support while decreasing the strength of mismatched hybridization reactions between the mixed base sequence oligonucleotide capture probe and any nucleic acid sequences.
closely resembling the true target. Two surprising aspects of the TEA C1 wash in the present system are
that (1) non-specific binding of the labeled probe to the solid support is decreased while, (2) hybridization
signals are increased when the wash is applied prior to the addition of labeled probe.

It has now been shown that the level of subsequent binding of the labeled probe to captured targets is
increased by up to a factor of eight when the TEA C1 wash step is applied prior to the addition of the
labeled probe. Washing with TEA C1 prior to the addition of labeled probe causes a decrease in the level of
the nonspecific binding of the labeled probe to the support during the subsequent labeling reaction. Similar
results have been demonstrated with 2.4M TEA Br and can be predicted with the use of related
salts/solvents.

Without wishing to be bound by theory, it is believed that the TEA cations remain bound to the poly-
(dA)-poly(dT) for a significant period of time and somehow alter the structure of the immobilized probe-
target complex with the result that the target becomes more accessible to incoming riboprobes, thus
increasing the hybridization efficiency. For example, the target rRNA may have its elaborate secondary
structure relaxed in TEA C1. Oroz and Wetmur, (1977), Biopolymers, 16:1183-1199 describe the relative
instability of the RNA-RNA double helix in TEA C1. For a short period of time the target may be more
accessible to the incoming riboprobe, causing an overall increase in the level of hybridization.

In addition to the format described above, the present method can be used in a "reversible target
capture" format. By "reversible target capture" is meant the following process: A target is immobilized on a
first solid phase. The first solid phase is washed and the target is removed by addition of the first elution
buffer and immobilized on a second solid phase. The second solid phase is washed, and, optionally, the
target is removed with a second elution buffer and immobilized on a third solid phase. The process can be
repeated as often as desired. The process of reversible target capture greatly enhances the signal/noise
ratio of the hybridization assay. The solid phases can be the same or different; the elution buffers can be
the same or different. Generally, maximum signal/noise ratios are achieved when both the solid phases and
the elution buffers are different.

Formats for reversible capture include, for example:
1. Targets are captured with short-tailed (e.g., having a dA tail about 15 nucleotides long) oligomer
probes (about 35-50 nucleotides in length) which are prebound to polystyrene, in a tetraalkylammonium
salt. If desired, a specific labeled probe can be added during the first capture. If a generic labeled probe
is desired, it can be added to the elution buffer. Elution is performed using 2.5 M GuSCN and recapture
is done with a second oligonucleotide containing a longer tail (e.g., a dA-50 or dA-100 tail) which will form
stable hybrids with poly(dT) in 2.5 M GuSCN. (2 oligoprobe specificity, 3 if a specific labeled probe was
used).
2. Targets are captured with short-tailed (e.g., about 15 nucleotides) oligomer probes (e.g., about 35-50
nucleotides in length) prebound to polystyrene in a tetraalkylammonium salt. If desired, a specific labeled
probe can be added during the first capture. If a generic labeled probe is desired, it can be added to the
elution buffer. Elution is performed with 2.5M GuSCN. GuSCN is then diluted so that the short tailed
probe can rebind to poly(dT). (1 oligo probe specificity or 2 if a specific labeled probe was used).
3. Targets are captured with a short oligomer (e.g. about 15-20 nucleotides) and a long tail (e.g., dA-100
or more). A specific labeled probe can be used during the first capture; a generic labeled probe is best
used during the elution. The target is then released by contacting with a tetraalkylammonium salt that
stabilizes poly(dA)--poly(dT) relative to mixed base sequences. The tagged probe remains bound to the
support; the target is released. The target is then recaptured with a second specific oligomer to improve
the specificity of the hybridization and reduce the nonspecific binding of excess labeled probe to the
solid supports. (2 oligo probe specificity, 3 if a specific labeled probe was used).
4. In the preferred method, the first capture probe is prebound to the first solid support. A second mixed
base sequence can be prebound to the second solid support. The next step is to capture the target on
the first solid support. A specific labeled probe is best added during the first capture while a generic
labeled probe is best added to the elution buffer. Elution is done in such a way as to remove only the
target, or the target and the first capture probe. It is preferable to add a specific labeled probe to the
elution buffer if the process of elution would dissociate a previously added labeled probe from the target.
The sample is either cooled or diluted, as required, and added to the second solid support. The poly(dT)
of the second solid support was pre-saturated with the second capture probe well enough to prevent any
significant rebinding of the target to the second support through the tail of the first capture probe.
In other words, the target is forced to rebind to the support by hybridization to the second specific mixed
base sequence (2 oligo probe specificity, or 3 oligoprobe specificity if a specific oligomer labeled probe
was used).
By adding an appropriate amount of poly(dT) to the elution buffer, the poly(dA) of the first capture probe can be prebound to the poly(dT) in solution before it has a chance to bind to the second support. This method has been employed successfully to block poly(dA)-containing molecules from binding to poly(dT) supports containing prebound tailed probes in a co-pending U.S. patent application entitled "Methods and Apparatus Useful in Preventing Endogenous Substances from Interfering with Affinity Capture Schemes" by Collins, Gillespie and Morrissey, Serial No. 07/322,419, filed March 10, 1989, the teachings of which are incorporated herein by reference.

Poly(dA) can be incubated with the second solid phase prior to the addition of the sample that eluted from the first solid phase with the first tailed probe. This will effectively preblock any free poly(dT) on the second solid phase so that no poly(dA) from the first tailed probes can bind to the second solid support.

It should be noted that the procedures described above are not limited to just two captures, but can be extended to any desired number of captures. However, if more than two are employed, the assay is more suitable to automation than for manual use. In addition, the second or even the third solid phases (with triple capture) do not have to be of the same chemical composition as the first. Indeed, advantages have been disclosed for the use of very different solid phases in reversible target capture (Collins, European Patent Application Number 87309308.2).

The assay steps of the present method can be readily automated. This is especially so with microtiter plates as the solid phase, since automatic pipetting equipment (for reagent addition and washing steps) and color readers already exist for microtiter plates. An automated device for carrying out the present invention can comprise: a pipetting station and a detection apparatus, said pipetting station being capable of performing sequential operations of adding and removing reagents to the solid phase at specific time points in a thermostatted environment (i.e., temperature controlled environment). The sequential operations include one or more of the following: mixing or contacting samples, lysis solutions and solid support, withdrawing fluid from the supports, adding wash buffer, repeating the steps enumerated above, adding labeled probes, repeating the wash steps again, adding detection agents, and detecting the signal with the detection apparatus.

The present preimmobilized oligonucleotide probes and method of using them can be incorporated into a kit for clinical use. Such a kit would include solid supports each having bound thereto a substratum, and one or more specific tailed capture probes prehybridized to the substratum. The substratum will preferably be a homopolynucleotide, such as poly(dT). The kit can also contain lysis solutions or other chaotropic agents, and a labeled probe for detecting and quantifying target nucleic acids. The kit can optionally contain wash buffers, a means for detecting the labeled probe, one or more elution buffers, amplification or cloning reagents, and/or one or more positive control samples and one or more negative control samples. Amplification of the target sequences can be accomplished, for example, by the technique described by Mullis in U.S. Patent 4,683,202. Cloning of the target sequences can be accomplished, for example, by the method disclosed by Maniatis in Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1982).

The invention will now be further illustrated by the following examples, which are not intended to be limiting in any way.

EXAMPLES

Example 1

This example shows that laying down a poly(dT) substratum on polystyrene greatly increases the ability to bind the preferred oligonucleotide capture probes to this solid phase, which in turn improves the ability to do target capture on this support. It further discloses methods for preparing multilayered substrata to increase the binding capacity of the support for the capture probes, and thus, to increase the speed and efficiency of target capture.

Materials and Methods

Coating of Polystyrene with Poly(dT)

The following procedure is for coating microtiter wells, but has also been used successfully for coating polystyrene tubes and dipsticks such as those produced by Hygeia, Inc. (Newton, MA). Removable strips were used to customize the number of wells to be used per test. A volume of 0.3ml of 3 OD/ml poly(dT) in 1.5M NaCl, 0.3M Tris (pH8.0), 0.5M MgCl₂ per microtiter well (such as Dynatech Immulon 2) was sealed
and incubated overnight at 37 °C. The dT mixture was then removed from the wells, which were dried at 37 °C for 30 minutes. The dried wells were exposed to 650 μW/cm² of UV (254nm) for 2 minutes, washed three times with 1M NaCl, 100mM Tris (pH9.3), 2mM MgCl₂, 0.1% Tween 20, and air dried. Wells were blocked with 0.5M LiCl, 2.5% acetylated BSA, 10 μg/ml denatured E__.coli DNA, and 10 μg/ml tRNA for 1 hour at 65 °C, and washed three times as above. Alternatively, 2.5M GuSCN was substituted for 0.5M LiCl and the blocking was done at 37 °C instead of 65 °C.

**Determination of the Binding Capacity of poly(dT)-Coated Microtiter Wells**

To determine the binding capacity of the poly(dT) coated wells, 0.3ml of 32P 5’ end-labeled dA12 (5μg/ml) (Pharmacia) in the 1M NaCl wash buffer was added per well and incubated for 15 minutes at room temperature. The wells were washed three times with the above buffer and then scintillation counted. An acceptable dA12 binding capacity for rapid (i.e., 30-60 min) capture was determined by experiment to be greater than or equal to 200 ng/well. Uncoated wells (no substratum) typically had a dA12 binding capacity of less than 1 ng/well.

The binding capacity for oligonucleotides was determined by binding 32P-labeled tailed oligos to poly(dT)-coated and uncoated (control) wells, which were blocked as described. A binding mixture of 2.5M GuSCN, 2.5% acetylated BSA, 200mM Tris (pH7.4), 40mM EDTA, and 2μg/ml of the labeled dA-tailed probe was added to microtiter wells with and without dT3000 coating as a negative control. The mixture was incubated at 37 °C for one hour, removed from the wells (and saved), and the wells were washed three times with the standard wash buffer. Both the wells and the used binding mixture were scintillation counted. To determine the amount of tailed probe bound to the wells, the following formulas were used with C defined as capacity (in micrograms):

\[
cpm_{\text{bound}} = \frac{cpm_{\text{added}} - cpm_{\text{removed}}}{S_a \text{ probe (cpm/μg)}}
\]

From the known specific activity (S_a) of the probe, the amount of tailed probe bound per well was calculated. The results of the two methods showed excellent agreement.

**Preparation of Tailed Capture Probes**

Oligonucleotide probes were tailed overnight at 37 °C in 0.1M potassium cacodylate (pH7.0), 4mM MgCl₂, 1mM 2-mercaptoethanol, 0.1mg/ml acetylated BSA, dATP-oligonucleotide at a 50:1 to 150:1 molar ratio, and 1000 units per ml of TdT (Supertech). A small amount of tritium labeled dATP was added to the reaction in order to be able to determine tail length and the amount of tailed probe bound per well.

**Results**

The Salmonella specific 35mer oligo probe #678 (Figure 3) was 5’ end-labeled with 32P to a specific activity of 10^6 cpm/μg and tailed with either 30 dA residues or 110 dA residues. The probes were bound to blank microtiter wells and crosslinked with UV as described for the poly(dT) immobilization procedure or they were hybridized to poly(dT)-polystyrene wells in 2.5M GuSCN at 37 °C as described. The wells which were not coated with poly(dT) bound an average (of five wells) of 1 ng of the dA-30 probe and 0.8 ng of the dA-110 probe, a capacity much too low to be useful in a rapid assay format. Surprisingly, an average of 417 ng of the shorter tailed probe and 323 ng of the longer tailed probe were bound to the polystyrene wells coated with the negative control dT3000 substratum, which is significantly higher than what is reported in the prior art with random sequence DNA. Surprisingly, the ability to bind the preferred oligonucleotide capture probe to polystyrene was increased 300-500x fold by using the poly(dT) substratum.

While virtually no dA-tailed oligonucleotide bound to untreated polystyrene using the prior art methods, a substantial amount of the tailed oligonucleotide probe was immobilized on the poly(dT) coated support. Typical levels of bound capture probe range form 250 to 500 ng per well with the entire range producing acceptable results in assays. A larger difference in the amount of probe bound in relation to tail length would be expected. A shorter tail should allow an increased amount of oligonucleotide to bind, although the oligomer with the longer tail is probably not binding to the poly(dT) with all of the nucleotides in its tail.
Increased binding of the tagged probes to the poly(dT)-coated supports has been achieved by increasing the concentration of the oligonucleotide in the binding mixture to 5.0μg/ml-10.0μg/ml.

The concept of binding a layer of poly(dT) to polystyrene to allow the binding of a multiplicity of tagged oligonucleotide capture probes, which by themselves do not bind to polystyrene, can be further generalized. For example, tagged probes containing a multiplicity of properly spaced secondary ligands can be bound to poly(dT) polystyrene as above. The multiplicity of secondary ligands constitute the second layer or second substrate. Thus many first probes or other adaptor molecules can bind to the polystyrene and each of them would be capable of binding a plurality of additional capture probes (potentially bound to a target). In this way the capacity of the polystyrene solid support can be increased to any desired level to improve the speed and efficiency of the capture of target molecules.

Example 2

The present invention provides the same assay sensitivity as previous techniques that employ a capture probe free in solution. The rate of capture with the present method is, surprisingly, only slightly slower than the rate with the capture probe free in solution. The rate of capture is thus sufficient for practical clinical use.

Materials and Methods

Coating of polystyrene with poly(dT) and tailing of capture probes were performed as described in Example 1.

Synthesis of Labeled Generic Riboprobe

A 5’ 567bp fragment of the E. coli 16S rRNA was cloned into the pGEM4 vector. (Promega Biotec) It was transcribed with T7 polymerase using bio-11-UTP (Enzo) according to the manufacturer’s instructions (Promega Biotec). The resulting riboprobe was then purified by two rounds of ethanol precipitation. This probe is capable of hybridizing through short stretches of homology to all eubacterial 16S rRNA for which sequence information is available. It has been shown to hybridize to E. coli, Shigella, Salmonella, Campylobacter, Listeria, Neisseria gonorrhoea, and Chlamydia trachomatis.

Binding of dA-tailed Oligonucleotide Probes to Poly(dT) Coated Microtiter Wells Prior to Target Capture

A binding mixture of 2.5M GuSCN, 200mM Tris pH7.4, 40mM EDTA, 2.5% acetylated BSA, and 2.5μg/ml of the dA-tailed probe was added to preblocked microtiter wells with and without (negative control) T30000 coating. The mixture was incubated at 37°C for one hour, removed from the wells (and saved), and the wells were washed three times with the standard wash buffer. Both selected wells and the used binding mixture were scintillation counted. To determine the amount of tagged probe bound to the wells, the formula set out in Example 1 was used. The two methods used to calculate capacity were in excellent agreement. Control wells which were not coated with poly(deoxythymidylate bound an average (of five wells) of 1 ng of tagged probe. Poly(dT) wells typically bind 300-500 ng of tagged probe, depending on the tail length.

Use of Pre-bound Capture Probes in a Nonisotopic Assay

Capture probes can be immobilized either on polystyrene microtiter wells, polystyrene tubes or dipsticks, or other configuration, with all supports functioning equally well for assaying clinical samples. Most of the work has been done with microtiter wells, thus, the following procedure is tailored specifically for this support, though with alterations in volumes, it is easily adapted to dipsticks and tubes.

Three volumes of 1.3X processing buffer (3.25M GuSCN, 0.4M Tris pH7.4, 0.08M EDTA, 13% dextran sulfate, 1% Sarkosyl) were added to clinical samples. After vortexing for 30 seconds at top speed, 300μl of sample was added to each microtiter well and capture of targets by the pre-bound probe was allowed to occur for 40 minutes at 37°C. (Capture time varies, depending on length of the dA tail on the probe, with approximately one minute allowed for each dA). The samples were then removed from the wells, which were washed with 2.4M tetraethyl ammonium chloride (TEA Cl) for 15 minutes at 37°C. This was followed by the usual high salt wash. A 300 μl volume of a biotinylated generic riboprobe mixture was added per well and incubated for 30 minutes at 37°C. This mixture contained 0.5-1.0 μg/ml of the riboprobe, 2.5M
GuSCN, 0.2M Tris pH7.5, 0.01M EDTA, and 10% dextran sulfate. The riboprobe mixture was then removed from the wells, which were washed three times, and the enzyme conjugate (diluted 1:500) was added to the wells (300 µl/well) and incubated for 10 minutes at room temperature. This was followed by three to five washes with the NaCl wash buffer and then the addition of the enzyme substrate pNPP (1 mg/ml) in 1X diethanolamine buffer (Kirkegaard and Perry). The optical density at 405nm was read when the background on the negative control wells started to appear.

Results

To be a viable rapid assay method for clinical use, the pre-bound probes must function about equally well as capture probes free in solution. That is, the signal/noise ratio must not be significantly worse with the preimmobilized probe and it must not be so slow as to be impractical in a rapid assay format. In order to make this comparison, Campylobacter cell extracts were assayed using a pre-bound capture probe, and also with the hybridization of the capture probe occurring in liquid phase. A Campylobacter specific probe and the target containing 85 dA residues on the 3' end, (hereafter referred to as probe #732 shown in Figure 3), was bound to poly(dT)-3000 coated microtiter wells as described above. A 300ul volume of 2.0 x 10^6 Campylobacter cells/ml in 1.0 x 10^8 E. coli/ml in 2.5M GuSCN, 10% dextran sulfate was added to wells with pre-bound #732 probe and incubated for the times indicated in Figure 1. As a control, samples containing 1 x 10^6 E. coli/ml, but no Campylobacter, were incubated under similar conditions. In parallel, the same samples were preincubated for one half hour with 1 µg/ml of dA-tailed #732 and 1 µg/ml biotinylated generic riboprobe, and added to poly(dT) coated wells for the indicated times. All wells were incubated for the indicated times at 37°C and then washed three times with 1M NaCl, 0.1M Tris pH 9.3, 2mM MgCl2, 0.1% Tween 20. The standard assay procedure was then followed as described above for detection. Figure 1 shows that essentially no difference in the maximum signal was observed between the assay performed with the capture probe either preimmobilized on poly(d)-coated polystyrene or free in solution. Backgrounds were subtracted from signals in generating Figure 1 and were negligible in all cases (less than or equal to 2% of the maximum signal).

A surprising result was that the rate of capture with the dA-65 tailed preimmobilize capture probe was only slightly slower than with the same capture probe free in solution. In Figure 1, capture is substantially complete in 60 minutes with the capture probe-target complex free in solution and with the dA-65 tailed probe prebound to the support. The capture kinetics with both the free and the preimmobilized tailed probe depends on the tail length. For the preimmobilized tailed probe, the optimal capture time is approximately one minute for each dA residue in the tail; that is, with a tail length of 40, 40 min is allowed for capture; with a tail length of 90, 90 min is allowed for capture. The preferred tail length is about 30-40 nucleotides for quick, efficient capture in 2.5 M GuSCN.

The high concentration of preimmobilized capture probe achieved by the present invention helps to make the hybridization to the target occur quickly. The overall assay times for the two formats are thus about the same (about 2 hours). Table 1 presents a summary of the time required for each step in the method.

<table>
<thead>
<tr>
<th>Step</th>
<th>Time Required</th>
</tr>
</thead>
<tbody>
<tr>
<td>Process samples</td>
<td>2 min/sample</td>
</tr>
<tr>
<td>Capture with preimmobilized oligos</td>
<td>40 min</td>
</tr>
<tr>
<td>TEA C1 stringency wash</td>
<td>15 min</td>
</tr>
<tr>
<td>Label with generic riboprobe</td>
<td>30 min</td>
</tr>
<tr>
<td>Wash and detect nonisotopically</td>
<td>30 min</td>
</tr>
</tbody>
</table>

Note: 20 stool samples have been conveniently assayed in under 3 hours by this method. The capture time is that for a 40mer dA-tail on the capture probe.

Another factor that is thought to contribute to the unexpected lack of difference in capture kinetics between the free and bound capture probe with a 65mer tail length is that prebound capture probe should still have some mobility in its interaction with the target, since it is anchored to the support only through its tail. If it were nonspecifically immobilized to the solid support through its mixed base sequence (as are
Example 3

This example shows that there was no crosstalk among dipsticks containing different prebound probes when these dipsticks were immersed in the same sample. It was shown that the reason for the absence of crosstalk is that the capture probe remains stably bound to the poly(dT) throughout the assay.

When using a number of polystyrene dipsticks in the same sample, each with a different bound capture probe, it is possible that some of the noncovalently bound probe could migrate from one support to another. This phenomenon could result in diminished signals and/or in increased backgrounds. The following experiment was performed in order to see if such "crosstalk" occurs with this method of attaching oligonucleotide probes to polystyrene supports.

A Campylobacter specific dA40-tailed probe (probe # 732, Figure 3) and a nonsense sequence control probe (probe # 574, Figure 3) were bound to poly(dT)-coated polystyrene microtiter wells. These wells were then used in an assay in two different ways: the first being as microtiter wells and the other as "dipsticks" with the entire well being submerged into a sample.

A normal stool sample processed in 2.5M GuSCN, 10% dextran sulfate was assayed with and without the addition of Campylobacter extract at 5.06 cells/ml. Each point was done in triplicate with a total of six "dipstick" wells being added to 10 ml of each stool sample and 300 μl of sample being added to each microtiter well. Capture was allowed to occur for forty minutes at 37 °C and was followed by a TEA C1 wash (equal volumes as samples) for fifteen minutes at 37 °C. At this point, all of the supports were treated as standard microtiter wells and the protocol described in the Materials and Methods Section was followed. The optical density at 405 nm was read 10 and 30 minutes after the addition of the enzyme substrate. The experiment was repeated using the Salmonella-specific capture probe 676 (Figure 3) as a control instead of the 574 control probe. In this case, the OD 405 nm was read ten and twenty minutes after the addition of the enzyme substrate. The data of Table 2 shows that neither diminished signals nor any increase in background was observed when "dipsticks" with different bound probes were placed in the same sample.
<table>
<thead>
<tr>
<th>Sample</th>
<th>Support</th>
<th>OD 405nm 10 min.</th>
<th>OD 405nm 30 min.</th>
</tr>
</thead>
<tbody>
<tr>
<td>unspiked stool</td>
<td>dipstick</td>
<td>732</td>
<td>0</td>
</tr>
<tr>
<td>&quot;</td>
<td></td>
<td>576</td>
<td>0.044</td>
</tr>
<tr>
<td>stool + campy</td>
<td>&quot;</td>
<td>732</td>
<td>1.474</td>
</tr>
<tr>
<td>&quot;</td>
<td></td>
<td>576</td>
<td>2.0</td>
</tr>
<tr>
<td>unspiked stool</td>
<td>well</td>
<td>732</td>
<td>0.004</td>
</tr>
<tr>
<td>&quot;</td>
<td></td>
<td>576</td>
<td>0.064</td>
</tr>
<tr>
<td>stool + campy</td>
<td>&quot;</td>
<td>732</td>
<td>0.009</td>
</tr>
<tr>
<td>&quot;</td>
<td></td>
<td>576</td>
<td>0.060</td>
</tr>
<tr>
<td>unspiked stool</td>
<td>dipstick</td>
<td>732</td>
<td>0</td>
</tr>
<tr>
<td>&quot;</td>
<td></td>
<td>676</td>
<td>0.014</td>
</tr>
<tr>
<td>stool + campy</td>
<td>&quot;</td>
<td>732</td>
<td>0.006</td>
</tr>
<tr>
<td>&quot;</td>
<td></td>
<td>676</td>
<td>0.009</td>
</tr>
<tr>
<td>unspiked stool</td>
<td>well</td>
<td>732</td>
<td>0</td>
</tr>
<tr>
<td>&quot;</td>
<td></td>
<td>676</td>
<td>0.014</td>
</tr>
<tr>
<td>stool + campy</td>
<td>&quot;</td>
<td>732</td>
<td>0.022</td>
</tr>
<tr>
<td>&quot;</td>
<td></td>
<td>676</td>
<td>0.017</td>
</tr>
</tbody>
</table>

Legend: Filtered GTS normal stool #14 in 2.5M GuSCN, 10% dextran sulfate was spiked with Campylobacter extract at 5.0E6 cells/ml. In the first experiment an average of 556ng of 732 and 316ng of 576 were bound per poly(dT) coated well, and in the second, 445ng of 732 and 350ng of 676. To each well was added 300ul of sample and six "dipstick wells" were added to 10ml of sample. After the TEA C1 wash (in volumes equal to those of the samples), the "dipsticks" were treated as normal microtiter wells and the standard protocol was followed. Results are the average of triplicate samples.
As compared to the results from the wells, the backgrounds from the "dipsticks" were slightly lower (not significantly higher, as predicted if crosstalk occurs) and the positive signals were actually greater (not less, as predicted if crosstalk occurs). The increase in signal seen with the wells used as dipsticks could be due to the larger sample volume available to the wells immersed in the samples coupled with target driven hybridization at this level of target. In any case, the higher signals achieved with the actual immersion of the solid phase as compared to the use of microtiter wells is one advantage of using dipsticks as the solid phase in place of microtiter wells. Another advantage of dipsticks over wells is that sample handling and pipetting are minimized.

Most likely, the absence of crosstalk is due to the tailed probe's remaining bound to the support throughout the capture. Additionally, if a small amount of loosely bound tailed probe does elute from a given dipstick, very little can rebind to other dipsticks since the vast majority of the poly(dT) on the other sticks have been pre-saturated with their own tailed probes. An experiment was done in order to measure the stability of the prebound tailed probe during the course of the assay. The tritium labeled, dA-tailed capture probe 732 (dA80) was pre-bound in 2.5M GuSCN, 10% dextran sulfate to dT4000 coated and blocked polystyrene microtiter wells with an average dA12 binding capacity of 412ng. Twelve wells were scintillation counted prior to the assay in order to establish a baseline for the amount of probe immobilized on the supports. The results are presented in Table 3. A mean value of 274 ng of probe bound per well was obtained. Twenty-four wells were then carried through a mock assay which included all of the normal steps and reagents, except that no target or riboprobe were added. Twelve wells were assayed with the standard 2.5M GuSCN, while the other twelve were done with 2.0M GuSCN. 2.0M GuSCN was used because it effectively controls RNase, and oligo(dA) binds to poly(dT) better in 2.0M GuSCN than in 2.5M GuSCN. The wells were incubated with 2.5M or 2.0M GuSCN and 10% dextran sulfate for 40 minutes at 37°C, followed by a 2.4M TEA C1 wash for 15 minutes at 37°C. After three washes with 1M NaCl, 0.1M Tris pH9.3, 2mM MgC12, 0.1% Tween 20, the wells were incubated once again with GuSCN and 10% dextran sulfate for 30 minutes at 37°C. Following three washes with the above NaCl buffer, the wells were incubated with the enzyme conjugate dilution buffer for 10 minutes at room temperature. The wells were washed three times with the NaCl buffer and then scintillation counted. (The enzyme substrate step was excluded since it may actually be advantageous if the probe came off of the solid support during color development). As seen in Table 3, a mean value of 198 ng of probe retained per well in those which were assayed with 2.5M GuSCN. Based on the pre-assayed values, 72% of the immobilized probe remained bound to the solid supports. For the wells assayed with 2.0M GuSCN, the mean value retained was 218ng per well, or 79% of the established baseline. This shows that very little capture probe comes off the support during the course of an assay with the present invention.
<table>
<thead>
<tr>
<th></th>
<th>Pre-Assay</th>
<th>2.5M GuSCN Assay</th>
<th>2.0M GuSCN Assay</th>
</tr>
</thead>
<tbody>
<tr>
<td>cpm/well</td>
<td>ng/well</td>
<td>cpm/well</td>
<td>ng/well</td>
</tr>
<tr>
<td>15623</td>
<td>223</td>
<td>12710</td>
<td>181</td>
</tr>
<tr>
<td>21056</td>
<td>301</td>
<td>14001</td>
<td>200</td>
</tr>
<tr>
<td>20615</td>
<td>294</td>
<td>13950</td>
<td>199</td>
</tr>
<tr>
<td>22436</td>
<td>320</td>
<td>16040</td>
<td>229</td>
</tr>
<tr>
<td>17037</td>
<td>243</td>
<td>11269</td>
<td>161</td>
</tr>
<tr>
<td>19693</td>
<td>281</td>
<td>13434</td>
<td>192</td>
</tr>
<tr>
<td>18944</td>
<td>271</td>
<td>14705</td>
<td>210</td>
</tr>
<tr>
<td>17898</td>
<td>256</td>
<td>15822</td>
<td>213</td>
</tr>
<tr>
<td>21055</td>
<td>301</td>
<td>15051</td>
<td>215</td>
</tr>
<tr>
<td>20405</td>
<td>291</td>
<td>13281</td>
<td>190</td>
</tr>
<tr>
<td>16609</td>
<td>237</td>
<td>13947</td>
<td>199</td>
</tr>
<tr>
<td>18680</td>
<td>267</td>
<td>12658</td>
<td>181</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>2.5M GuSCN Assay</th>
<th>2.0M GuSCN Assay</th>
</tr>
</thead>
<tbody>
<tr>
<td>mean:</td>
<td>274</td>
<td>198</td>
</tr>
<tr>
<td>std. dev.:</td>
<td>28.3</td>
<td>17.5</td>
</tr>
<tr>
<td>% retained:</td>
<td>72%</td>
<td>79%</td>
</tr>
</tbody>
</table>

Legend: Polystyrene microtiter wells were coated with poly(dT)-4000, UV irradiated, and blocked as described. The 3H-labeled, dA-tailed capture probe 732 (dA80) was bound to wells in 2.5M GuSCN, 10% dextran sulfate. Twelve wells were scintillation counted prior to the start of the assay in order to obtain a baseline of the amount of probe bound. A mock assay (no target or riboprobe added) was done with 24 wells, 12 of which were used with 2.5M GuSCN and 12 with 2.0M GuSCN. After the final wash step, the wells were scintillation counted and the percent of the capture probe retained on the wells was calculated.
The retention of the preimmobilized probe is thus about 70-80% during the course of the entire assay. Crosstalk is most likely to occur, if at all, during the first forty minute capture step. During the capture step, retention of bound capture probe is greater than 93%.

It is also possible to add Poly(dT) to the samples to bind to the dA-tails of any probes that elute from their respective dipsticks. This would prevent the dA-tailed probes from binding to a small amount of unhybridized poly(dT) on other dipsticks (by choosing the appropriate concentration of poly(dT), the solution phase hybridization will be faster than the solid phase immobilization).

Poly(dA) could be added to the samples in place of poly(dT) in sufficient quantity such that any free poly(dT) on the dipsticks will preferentially bind the added poly(dA), and not the tailed probes from other dipsticks.

Example 4

This example shows that the present invention can be used to assay clinical stool specimens nonisotopically with no cell culture and without prior purification of the nucleic acids. The sensitivity and specificity are each about 90%.

In two separate experiments, a total of 32 Campylobacter culture-positive stool samples (obtained from Evanston Hospital, Evanston IL), and 20 "normal" and culture-negative specimens, were assayed using a pre-bound Campylobacter specific 16S rRNA capture probe (#732). The 732 probe is 35 nucleotides in length and recognizes C. jejuni, C. coli, and C. lariid, but misses all other Campylobacter species, including C. fetus and C. pylori. The standard assay protocol described in the Materials and Methods section of Example 2 was used. The OD 405nm was read 45 minutes after the addition of the enzyme substrate. For each sample, the level of specific hybridization was computed as the OD 405nm of the 732 probe well minus that of the control well containing only calf thymus DNA. The cut off for positives was set at twice the average of the negative samples assayed in each experiment. Table 4 shows that of the twenty negative stool samples screened, three were scored as false positive (85% specificity). Better specificity can be achieved by using two specific probes in place of one specific and one generic probe. Significantly, two of the three false positives were from "normal" samples, some of whom may have an asymptomatic low level Campylobacter infection from prolonged exposure to the pathogen. These samples were not confirmed culture negatives. With confirmed culture negatives, the assay showed one false positive (90% specificity).
Table 4: Assay of Normal and Culture Negative Stools with the Campylobacter Probe #732

<table>
<thead>
<tr>
<th>Sample</th>
<th>732</th>
<th>CT</th>
<th>732-CT</th>
<th>+/-</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>0.106</td>
<td>0</td>
<td>0.106</td>
<td>+</td>
</tr>
<tr>
<td>2</td>
<td>0.006</td>
<td>0</td>
<td>0.006</td>
<td>-</td>
</tr>
<tr>
<td>3</td>
<td>0.122</td>
<td>0</td>
<td>0.122</td>
<td>+</td>
</tr>
<tr>
<td>4</td>
<td>0.035</td>
<td>0</td>
<td>0.035</td>
<td>-</td>
</tr>
<tr>
<td>5</td>
<td>0.030</td>
<td>0</td>
<td>0.030</td>
<td>-</td>
</tr>
<tr>
<td>6</td>
<td>0.072</td>
<td>0.028</td>
<td>0.044</td>
<td>-</td>
</tr>
<tr>
<td>7</td>
<td>0.052</td>
<td>0</td>
<td>0.052</td>
<td>-</td>
</tr>
<tr>
<td>8</td>
<td>0.078</td>
<td>0.031</td>
<td>0.047</td>
<td>-</td>
</tr>
<tr>
<td>9</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>-</td>
</tr>
<tr>
<td>10</td>
<td>0.028</td>
<td>0</td>
<td>0.028</td>
<td>-</td>
</tr>
</tbody>
</table>

Cut off for positives: 0.094 (2x the avg. of negs.)

Experiment B: Clinical Campylobacter culture-negative stools.

<table>
<thead>
<tr>
<th>Sample</th>
<th>732</th>
<th>CT</th>
<th>732-CT</th>
<th>+/-</th>
</tr>
</thead>
<tbody>
<tr>
<td>2047</td>
<td>0.107</td>
<td>0</td>
<td>0.107</td>
<td>-</td>
</tr>
<tr>
<td>2048</td>
<td>0.045</td>
<td>0</td>
<td>0.045</td>
<td>-</td>
</tr>
<tr>
<td>2055</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>-</td>
</tr>
<tr>
<td>2061</td>
<td>0.071</td>
<td>0.001</td>
<td>0.070</td>
<td>-</td>
</tr>
<tr>
<td>2065</td>
<td>0.124</td>
<td>0.015</td>
<td>0.109</td>
<td>-</td>
</tr>
<tr>
<td>2070</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>-</td>
</tr>
<tr>
<td>2080</td>
<td>0.219</td>
<td>0.441</td>
<td>0</td>
<td>-</td>
</tr>
<tr>
<td>2081</td>
<td>0.391</td>
<td>0.032</td>
<td>0.359</td>
<td>+</td>
</tr>
<tr>
<td>2083</td>
<td>0.019</td>
<td>0</td>
<td>0.019</td>
<td>-</td>
</tr>
<tr>
<td>2084</td>
<td>0.095</td>
<td>0</td>
<td>0.095</td>
<td>-</td>
</tr>
</tbody>
</table>

Cut off for positives: 0.160 (2x the avg. of negs.)

Legend: See Table 5.

Table 5 shows that twenty-nine of the thirty-two Campylobacter positive clinical samples proved to be positive by the DNA probe assay (91% sensitivity). The three false negatives, which all showed absolutely no signal, may have been missed due to the somewhat limited inclusivity of the capture probe used. It is also possible that the samples were "mishandled" prior to assay since they were not collected and stored with an assay for a fragile molecule like RNA in mind.
Table 5: Assay of *Campylobacter* Clinical Samples

<table>
<thead>
<tr>
<th>CD 405nm</th>
<th>Sample</th>
<th>732</th>
<th>CT</th>
<th>732-CT</th>
<th>+/−</th>
<th>Culture</th>
</tr>
</thead>
<tbody>
<tr>
<td>Experiment A: Cut off for positives: 0.094</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2002</td>
<td>&gt;2</td>
<td>0</td>
<td>&gt;2</td>
<td>+</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2005</td>
<td>1.272</td>
<td>0</td>
<td>1.272</td>
<td>+</td>
<td>2P</td>
<td></td>
</tr>
<tr>
<td>2006</td>
<td>&gt;2</td>
<td>0</td>
<td>&gt;2</td>
<td>+</td>
<td>3P</td>
<td></td>
</tr>
<tr>
<td>2007</td>
<td>0.000</td>
<td>0</td>
<td>0</td>
<td>−</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2008</td>
<td>0.011</td>
<td>0.013</td>
<td>0</td>
<td>−</td>
<td>2P</td>
<td></td>
</tr>
<tr>
<td>2009</td>
<td>0.419</td>
<td>0.054</td>
<td>0.365</td>
<td>+</td>
<td>2P</td>
<td></td>
</tr>
<tr>
<td>2010</td>
<td>&gt;2</td>
<td>1.343</td>
<td>&gt;0.6</td>
<td>+</td>
<td>1P</td>
<td></td>
</tr>
<tr>
<td>2011</td>
<td>&gt;2</td>
<td>0</td>
<td>&gt;2</td>
<td>+</td>
<td>3P</td>
<td></td>
</tr>
<tr>
<td>2012</td>
<td>&gt;2</td>
<td>0.786</td>
<td>&gt;1.2</td>
<td>+</td>
<td>3P</td>
<td></td>
</tr>
<tr>
<td>2013</td>
<td>0.122</td>
<td>0</td>
<td>0.122</td>
<td>+</td>
<td>1P</td>
<td></td>
</tr>
<tr>
<td>2014</td>
<td>&gt;2</td>
<td>0</td>
<td>&gt;2</td>
<td>+</td>
<td>3P</td>
<td></td>
</tr>
<tr>
<td>2015</td>
<td>&gt;2</td>
<td>0</td>
<td>&gt;2</td>
<td>+</td>
<td>2P</td>
<td></td>
</tr>
<tr>
<td>2016</td>
<td>&gt;2</td>
<td>0</td>
<td>&gt;2</td>
<td>+</td>
<td>3P</td>
<td></td>
</tr>
<tr>
<td>2017</td>
<td>&gt;2</td>
<td>0</td>
<td>&gt;2</td>
<td>+</td>
<td>3P</td>
<td></td>
</tr>
<tr>
<td>2018</td>
<td>0.097</td>
<td>0</td>
<td>0.097</td>
<td>+</td>
<td>1P</td>
<td></td>
</tr>
<tr>
<td>2019</td>
<td>&gt;2</td>
<td>0</td>
<td>&gt;2</td>
<td>+</td>
<td>3P</td>
<td></td>
</tr>
<tr>
<td>2020</td>
<td>&gt;2</td>
<td>0</td>
<td>&gt;2</td>
<td>+</td>
<td>3P</td>
<td></td>
</tr>
<tr>
<td>2021</td>
<td>&gt;2</td>
<td>0</td>
<td>&gt;2</td>
<td>+</td>
<td>1P</td>
<td></td>
</tr>
<tr>
<td>2022</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>−</td>
<td>2P</td>
<td></td>
</tr>
<tr>
<td>2023</td>
<td>&gt;2</td>
<td>0</td>
<td>&gt;2</td>
<td>+</td>
<td>2P</td>
<td></td>
</tr>
<tr>
<td>2024</td>
<td>0.486</td>
<td>0</td>
<td>0.486</td>
<td>+</td>
<td>3P</td>
<td></td>
</tr>
<tr>
<td>2025</td>
<td>&gt;2</td>
<td>0</td>
<td>&gt;2</td>
<td>+</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2026</td>
<td>0.128</td>
<td>0</td>
<td>0.128</td>
<td>+</td>
<td>1P</td>
<td></td>
</tr>
<tr>
<td>2027</td>
<td>0.416</td>
<td>0</td>
<td>0.416</td>
<td>+</td>
<td>2P</td>
<td></td>
</tr>
<tr>
<td>2050</td>
<td>1.028</td>
<td>0</td>
<td>1.028</td>
<td>+</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2062</td>
<td>&gt;2</td>
<td>0</td>
<td>&gt;2</td>
<td>+</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Experiment B: Cut off for positives: 0.160

| 2064     | >2     | 0   | >2 |  + |     |
| 2090     | >2     | 0.148 | >1.8 | + | 4P |
| 2091     | >2     | 0   | >2 |  + | 4P |
| 2092     | >2     | 0   | >2 |  + | 4P |
| 2100     | >2     | 0   | >2 |  + | 3P |
| 2112     | >2     | 0.040 | >2 |  + | 3P |

Legend of Tables 4 and 5: The "732" column is the *Campylobacter* specific signal and the "CT" column is the nonspecific (calf thymus DNA) background. +/- refers to whether the sample is positive or negative by the DNA probe assay. Culture: 4P >> 3P >> 2P >> 1P. This represents a relative estimate of the number of *Campylobacter* colonies on the *Campylobacter* selective plate.

Example 5

This example shows the detection limit of the assay by measuring the dose-response of the technique for the detection of *Salmonella typhimurium* in 25% w/v normal stool.
In order to assess the detection limit of the assay described in this document, a dose-response study was done for the direct detection of Salmonella spiked into normal stool. Normal stool was spiked with various levels of Salmonella typhimurium and assayed following the standard protocol of example one but using the Salmonella specific capture probe #676 (Figure 3). As shown in Figure 2, the nonisotopic assay detection limit (without cell culture or prior purification of the nucleic acids) is approximately 1.2 x 104 Salmonella per sample. The signal at that level of Salmonella (0.038 OD) is about 10 times the assay background (0.004 OD).

Example 6

This example shows a useful, generic method whereby a stringency wash can be done with target immobilized on a solid support by means of the poly(dT)-poly(dA) affinity pair.

The wash step with 2.4M TEA C1 following capture of targets out of samples was originally added as a stringency wash in order to reduce nonspecific hybridization. 2.4 M TEA C1 functions as an agent that equalizes the strength of the AT and GC base pairs. This property can be exploited in assays employing a battery of probes of a fixed length but of widely different base composition. By washing with 2.4M TEA C1, all hybridizations can be made equally stringent. In this way a reduction of nonspecific hybridization can be accomplished with a TEA C1 wash.

Tetraalkylammonium salts have an added advantage for a capture system based on the dA-dT affinity pair: They greatly strengthen the poly(dA)-poly(dT) affinity pair (dissociation temperature of 65 °C in TEA C1) relative to 35mer mixed base sequences (dissociation temperature of 43-44 °C). This homopolymer thus enjoys an unexpected but useful stability. (Because of the equalizing of G-C and A-T base pairs in 2.4 M TEA C1, a plot of dissociation temperature versus probe length is a straight line. Wood et al. Proc. Natl. Acad. Sci. USA., vol 82, 1585-1588 (1985). This is true for random mixed base sequences. Poly(dA)-Oligo-(dT)-14 and poly(dA)-poly(dT) have dissociation temperatures much higher than predicted by their method.)

Because of the special stability of poly(dT)-poly(dA) in reagents such as TEA C1, a lot of pressure can be applied to dissociate the probe from pseudo-target sequences containing only one or a few mismatchs. The hybridization background can be greatly reduced under such washing conditions. The dA-dT pairing would normally break up under such stress and most of the signal would be lost with the background if it were not for the special and surprising strength imparted to the dA-dT homopolymer in reagents such as tetraalkylammonium salts.

Example 7

This example shows some further unexpected results obtained with the TEA C1 stringency wash.

Another surprising result was the reduction in nonspecific binding of the labeled probe to the support by washing the support PRIOR TO the addition of the labeled probe (Tables 6, 7, and 8). While the reduction of nonspecific hybridization of the probe to pseudo-targets is expected with TEA C1, the reasons for the reduction in nonspecific binding to the solid support are not completely understood. While in relatively clean samples the addition of the TEA C1 wash sometimes has little effect on nonspecific backgrounds, it does reduce the higher nonspecific backgrounds encountered in very dirty samples. The lower backgrounds in Table 6 seen with the samples washed with TEA C1 must be due to the decreased nonspecific binding of the labeled probe to the solid support since the control which has no heterologous target is the same as the control that has heterologous target. The lower E. coli 16S rRNA to form stable hybrids in 105 2.5M GuSCN at 37 °C).

Another surprising result obtained from the use of reagents such as TEA C1 for washing was the increase in signal when the wash step was done prior to the riboprobe hybridization. Wash steps do not normally increase hybridization signals. This can be seen in the results presented in Table 6, where the inclusion of the TEA C1 wash effectively doubled the signal from the Campylobacter sample (Campylobacter specific capture probe 732 used). The low nonspecific background from the E. coli and no cell control samples were further reduced by the TEA C1 wash.
Table 6: The Utility of the TEA Cl Wash in a Nonisotopic Assay

<table>
<thead>
<tr>
<th>Sample</th>
<th>TEA Cl</th>
<th>OD 405nm</th>
<th>732</th>
<th>576</th>
<th>732-576</th>
</tr>
</thead>
<tbody>
<tr>
<td>Campylobacter</td>
<td>-</td>
<td>0.744</td>
<td>0.016</td>
<td>0.726</td>
<td></td>
</tr>
<tr>
<td>E. coli</td>
<td>-</td>
<td>0.035</td>
<td>0.020</td>
<td>0.015</td>
<td></td>
</tr>
<tr>
<td>no cells</td>
<td>-</td>
<td>0.024</td>
<td>0.015</td>
<td>0.009</td>
<td></td>
</tr>
<tr>
<td>Campylobacter</td>
<td>+</td>
<td>1.487</td>
<td>0.021</td>
<td>1.466</td>
<td></td>
</tr>
<tr>
<td>E. coli</td>
<td>+</td>
<td>0.006</td>
<td>0.018</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>no cells</td>
<td>+</td>
<td>0.014</td>
<td>0.009</td>
<td>0</td>
<td></td>
</tr>
</tbody>
</table>

Legend: Campylobacter specific 732 capture probe was pre-bound to poly (dT) polystyrene wells. Cell extracts were diluted in 2.5M GuSCN, 10% dextran sulfate to 1.0E7 Campylobacter/ml or 1.0E9 E. coli/ml. After the capture step, the wells were emptied and 2.4M TEA Cl was added to the indicated wells and incubated for 15 minutes at 37 degrees. All wells were then washed 3x in the 1M NaCl wash buffer and the assay was continued using the standard protocol. The OD 405nm was read 30 minutes after the addition of the enzyme substrate. The results are the average of duplicate samples.

An experiment was done to determine if TEA Br produced the same effects in the assay as does TEA Cl (Table 8). TEA Br does cause a large increase in signal when used in a wash step prior to riboprobe hybridization. The TEA cation is thus responsible for the effects, although this does not imply that the anion is completely immaterial. Other cations, particularly similar cations, should have the same effect.

Table 7: Comparison of TEA Cl and TEA Br Washes

<table>
<thead>
<tr>
<th>OD 405nm</th>
<th>Wash</th>
<th>20 min.</th>
<th>60 min.</th>
</tr>
</thead>
<tbody>
<tr>
<td>unspiked stool</td>
<td>-</td>
<td>0.023</td>
<td>0.047</td>
</tr>
<tr>
<td>stool + Campy</td>
<td>-</td>
<td>0.082</td>
<td>0.183</td>
</tr>
<tr>
<td>unspiked stool</td>
<td>TEA Cl</td>
<td>0.030</td>
<td>0.055</td>
</tr>
<tr>
<td>stool + Campy</td>
<td>TEA Cl</td>
<td>0.525</td>
<td>1.620</td>
</tr>
<tr>
<td>unspiked stool</td>
<td>TEA Br</td>
<td>0.024</td>
<td>0.059</td>
</tr>
<tr>
<td>stool + Campy</td>
<td>TEA Br</td>
<td>0.488</td>
<td>1.504</td>
</tr>
</tbody>
</table>

Legend: Normal stool was assayed with and without the addition of Campylobacter extract to 1.0E6 cells/ml. The standard assay protocol was followed with the exception of the TEA Cl wash step, which was varied. In one set of samples it was included, in another it was replaced with TEA Br, and in another it was also excluded. Both the 2.4M TEA Cl and 2.4M TEA Br were autoclaved prior to use. The OD 405nm was read 20 and 60 minutes after the addition of the enzyme substrate. Results are the average of duplicate samples.
Another important aspect of this experiment is that about an eight-fold increase in signal was seen (with both TEA C1 and TEA Br) instead of the two-fold increase previously observed. This could be due to the fact that both reagents were autoclaved before use, which may have eliminated a low level nuclease activity which was previously present (and which thus may have lessened the potential signal enhancement).

In order to determine if the increase in signal seen with the use of reagents such as TEA C1 and TEA Br as wash buffers was due to improved binding of the riboprobe to the target or to a long range effect on alkaline phosphatase activity, an assay was done using a double labeled (^32P and biotin) riboprobe. Samples were assayed using the Campylobacter specific capture probe 732, with and without the inclusion of the TEA C1 wash following the standard protocol. The OD 405nm was read 40 minutes after the addition of the enzyme substrate and as expected, the Campylobacter positive signal was approximately doubled with the inclusion of the TEA C1 step (Table 8). Following color development, the wells were washed and then scintillation counted to determine the amount of riboprobe bound to the wells by way of the ^32P label. Approximately twice the number of counts were obtained in the Campylobacter wells which received the TEA C1 wash verses those which did not (The TEA C1 used in this experiment was not autoclaved). This corresponds to the increase in color obtained with the TEA C1 wash step, indicating that this improved signal is due to an increase in riboprobe binding. This increased binding of the riboprobe is believed to represent increased hybridization.
<table>
<thead>
<tr>
<th>Sample</th>
<th>TEA Cl</th>
<th>OD 405nm</th>
<th>CPM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Campy.</td>
<td>-</td>
<td>0.596</td>
<td>921</td>
</tr>
<tr>
<td>Campy.</td>
<td>+</td>
<td>1.073</td>
<td>1753</td>
</tr>
<tr>
<td>E. coli</td>
<td>-</td>
<td>0.089</td>
<td>244</td>
</tr>
<tr>
<td>E. coli</td>
<td>+</td>
<td>0.071</td>
<td>54</td>
</tr>
</tbody>
</table>

Legend: Cell extracts were diluted in 2.5M GuSCN, 10% dextran sulfate (Campylobacter to 1.0E6 cells/ml and E. coli to 1.0E9 cells/ml) and targets were captured with pre-bound 732 probe for 40 minutes at 37 degrees. The wells were washed with either 1M NaCl or with 2.4M TEA Cl for 15 minutes at 37 degrees. The target was then labeled with a + + + + + + + + + 16S rRNA generic riboprobe which was double labeled with biotin and 32P. After color development with SA-AP/pNPP for 40 minutes, the wells were washed and the amount of 32P bound was determined by scintillation counting.
While a slight decrease in the background from the E. coli sample was observed upon color development when the TEA C1 step was included, a far greater decrease (4.5x) in the amount of riboprobe bound to the wells was seen from the $^{32}$P counts obtained. This 4.5x reduction in background in the $^{32}$P counts represents the true decrease in the level of nonspecific binding of the riboprobe caused by the TEA C1 wash. The failure to see this same level of reduction in color is probably due to variable nonspecific binding of the enzyme conjugate streptavidin-alkaline phosphatase.

The data of Tables 6, 7, and 8 indicate that when the TEA C1 wash step is applied prior to the addition of the labeled probe, the level of subsequent binding (presumably hybridization) of the labeled probe to captured targets is increased by a factor of two or more.

Example 8

This example shows methods whereby the present probes can be used to do reversible target capture. The advantages of a reversible target capture protocol, particularly greatly increased sensitivity and specificity, are fully described in Collins, European Patent Application Number 265244, which has been incorporated herein by reference.

One important advantage of the dA-dT affinity pair used to capture the probe-target complex onto the solid support for the present invention is that it is readily reversible. Reversibility of target capture allows recapture of the target/probe complex onto other solid supports in order to reduce background levels and thus to improve the sensitivity and specificity of the assay. While the preferred user-friendly embodiment of the assay we describe in this document employs only a single capture for ease of use and yet has very good sensitivity and specificity in clinical stool samples, increased sensitivity and specificity may be gained by multiple rounds of capture. The experiment described below demonstrates the feasibility of the first such reversibility scheme. This method would use a capture probe with a very short, chemically synthesized dA tail, in this case dA15. The probe would be immobilized on a poly(dT) coated support in a tetraalkylammonium salt such as but not limited to 3.0M tetramethylammonium thiocyanate (TMA SCN). Tetraalkylammonium salts impart special stability to the poly(dA)-oligo(dT) affinity pair. Following the capture of the target from the sample and subsequent washes, the probe-target from the sample and subsequent washes, the probe-target complex would be eluted form the solid support in 2.5M GuSCN and then recaptured with a second probe with a long dA tail (either with the same or with a different mixed base sequence) on a second poly (dT) support with the same physical composition or with a different composition. As seen in Table 9, high levels of probe 888-dA15 (Figure 3) bind to poly (dT) coated polystyrene in 3.0M TMS SCN, but not in 2.5M Gu SCN. This shows that targets can be captured in 3.0M TMS SCN; then the probe-target complex can be eluted with 2.5 M Gu SCN to allow subsequent rounds of capture with a second probe containing a longer tail such that the probe-target complex can bind to the poly(dT) in 2.5 M Gu SCN. The concentration of the 888 probe required for acceptable levels of binding to the poly (dT) was increased from the standard concentration of 2.5 ug/ml due to the fact that a crude prep of the oligo was used in the immobilization procedure.
Table 9

<table>
<thead>
<tr>
<th>Hybrid. Sol.</th>
<th>Probe Conc.</th>
<th>ng bound/well</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.5M Gu SCN</td>
<td>2.5 ug/ml</td>
<td>28</td>
</tr>
<tr>
<td>3.0M TMA SCN</td>
<td>2.5 ug/ml</td>
<td>119</td>
</tr>
<tr>
<td>3.0M TMA SCN</td>
<td>5.0 ug/ml</td>
<td>374</td>
</tr>
<tr>
<td>3.0M TMA SCN</td>
<td>10.0 ug/ml</td>
<td>734</td>
</tr>
</tbody>
</table>

Legend: 32P labeled 5'dA-tailed 888 (dA15) probe was bound to poly(dT) coated polystyrene microtiter wells in 2.5M Gu SCN or 3.0M TMA SCN with 10% dextran sulfate for 1 hour at 37 degrees. Wells were pre-blocked with the standard blocking buffer containing 2.5M Gu SCN or with substitution by 3.0M TMA SCN. Following the incubation period with the probe, the wells were washed three times in the standard 1M NaCl wash buffer and then scintillation counted to determine the amount of probe bound. The data show that this short 5' tailed probe will bind to poly(dT) in 3.0 M TMA SCN but not in 2.5 M Gu SCN. The latter can thus be used as an elution buffer.
Example 9

This example discloses methods employed by the present invention to minimize signal loss due to the presence of large amounts of heterologous rRNAs, endogenous avidin, other biotin-binding molecules and other compounds.

When specimens are being tested for any of a group of pathogens, it is desirable to use a single labeled probe to label all of the targets of interest. For example, for a GI panel, a single large labeled probe (such as the 5' or 3' 16S riboprobe) containing many detectable ligands that would label the 16S rRNA of Campylobacter, Salmonella, and Shigella would be desirable in place of a vast multiplicity of singly or doubly labeled oligomers which would have to be made for each of the organisms (to achieve the same number of reporter groups bound per rRNA target).

However, in a stool sample there are generally more than $10^{11}$ bacteria/ml. Kuritza et al. Applied and Environmental Microbiology, 51:385-390 (1988). These bacteria would contain more than $10^{15}$ 16S rRNA per ml, and in a competitive situation, perhaps only 1/1000 rRNAs of the target organism will be labeled since the labeled probe concentration is only $10^{13}$/ml. This can be corrected by specifically capturing the target out of the stool sample and washing away competitor rRNAs prior to labeling.

Various substances besides rRNAs present inside cells can interfere with the labeling and detection of nucleic acid targets. For example, a biotinylated probe was used in the experiments reported herein. If large quantities of avidin or other biotin-binding macromolecules were present in the sample, these could bind to the biotinylated probe and reduce the size of the signal generated by the streptavidin-alkaline phosphatase. Capture of the target prior to labeling as disclosed herein is a workable solution to this problem.

Another potential interference is endogenous poly(rA) and poly(dA). Mammalian cells, which are found in virtually all clinical samples (especially blood) contain about 1 attomole of poly(rA) per cell. T. Maniatis, et al. 1982. Molecular Cloning: A Laboratory Manual, p. 188, Cold Spring Harbor Laboratory, New York. They also contain about 100 ppm poly(dA) by weight. These could compete with the dA-tailed probes potentially bound to targets for binding to the poly(dT) polystyrene. The result would be diminished signals and potentially higher backgrounds as well. By presaturating the support with tailed probes, this potential competition could be minimized or eliminated along with any potential increase in background.

In Table 10, data are presented from two representative experiments comparing the results employing either the preimmobilized capture probe or the capture probe free in solution. Three situations are considered: no competitors present (5X10^5 Campylobacter/ml only), competitor rRNA present (purified E. coli RNA added), or streptavidin present at 10 μg/ml. With the capture probe free in solution, there is a substantial loss of signal with competitor rRNA (34-fold decline) and streptavidin (100-fold), as predicted above.

With the preimmobilized capture probe, however, there was no loss in signal with competitor rRNA or with streptavidin. Thus this method allows us to exploit the advantages of using a single completely generic detector probe that is conveniently labeled with moieties such as biotin.
Table 10

Comparison of Competitor Effects on Solution and Immobilized Assay Formats

<table>
<thead>
<tr>
<th>Sample</th>
<th>SOLUTION</th>
<th>OD 405nm</th>
<th>IMMUNOLOGIZED</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Experiment A:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Campylobacter</td>
<td>1.209</td>
<td>1.044</td>
<td></td>
</tr>
<tr>
<td>Campylobacter + E. coli RNA</td>
<td>0.033</td>
<td>1.226</td>
<td></td>
</tr>
<tr>
<td>Campylobacter + Streptavidin</td>
<td>0.000</td>
<td>1.348</td>
<td></td>
</tr>
<tr>
<td><strong>Experiment B:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Campylobacter</td>
<td>0.962</td>
<td>0.796</td>
<td></td>
</tr>
<tr>
<td>Campylobacter + E. coli RNA</td>
<td>0.031</td>
<td>0.719</td>
<td></td>
</tr>
<tr>
<td>Campylobacter + Streptavidin</td>
<td>0.006</td>
<td>0.625</td>
<td></td>
</tr>
</tbody>
</table>

Legend: Campylobacter specific capture probe 732 (dA65) was used to assay Campylobacter extracts (5.0E6 cells/ml) in the presence of E. coli RNA (approx. 100 ug/ml), poly(A) (10 ug/ml), or streptavidin (10 ug/ml). Poly (dT) coated polystyrene dipsticks were used as a solid support for the capture of target molecules. Two different assay formats were used. In the first, dipsticks were added to samples along with the addition of the capture probe and the biotinylated riboprobe (both at 0.5 ug/ml) and incubated at 37 degrees for 60 minutes. The sticks were washed, incubated with a SA-AP conjugate, washed again, and then the signal was detected with pNPP. The second format used was the standard protocol with the capture probe immobilized on the dipsticks, the use of a TEA Cl wash step, and the addition of the labeled probe after the capture and TEA Cl steps. The capture step was for 60 min, and the riboprobe incubation for 30 min. A volume of 0.5 ml was used for all reagents except the 1M NaCl wash buffer (washes done in bulk). Results are the average of duplicates.
Equivalents
5 Those skilled in the art will recognize, or be able to ascertain by no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

Claims
10 1. A method for isolating or determining the presence or amount of a target nucleic acid in a sample, the method being of the type which involves the use of (i) an immobilizable capture probe comprising a tail and a target binding region which is a mixed base oligonucleotide sequence complementary to the target nucleic acid sequence and (ii) a substratum which is affixed to a solid support, the tail and the substratum together forming an affinity pair, characterized in that said method comprises the steps of:
15 (a) providing a polynucleotide substratum comprising a (dT) or (dA) homopolymer or the polymer of a simple repeating nucleotide sequence of (dT) and (dA), for example (dT)n, (dA)n, (dAdT)n or (dAdAdTdT)n, where n is sufficiently large to refer to a polymer of from about 50 to about 3000 nucleotides affixed to a solid polymeric support;
20 (b) contacting, under hybridizing conditions, the polynucleotide substratum with a capture probe consisting essentially of a target binding region and a tail which is an oligonucleotide or a polynucleotide, the sequence of which is complementary to the polynucleotide substratum, such that a first hybridized region is formed between the tail and the polynucleotide substratum to obtain a preimmobilized capture probe; and
25 (c) contacting the sample with the preimmobilized capture probe under hybridizing conditions, such that if the target nucleic acid is present in the sample, a second hybridized region is formed between the target nucleotide sequence and the target binding region of the capture probe to obtain an immobilized target nucleic acid.

30 2. A method according to claim 1, wherein:
(a) the tail of the capture probe is linked, for example synthetically or enzymatically linked, to the 3' end, the 5' end or at least one internal residue of the target binding region of the capture probe, provided however that the target binding region remains capable of forming the second hybridized region with the target nucleotide sequence; and wherein
35 (b) the target binding region of the capture probe is a DNA oligonucleotide and the tail is DNA or RNA; or
(c) the target binding region of the capture probe is a RNA oligonucleotide and the tail is DNA or RNA; or
(d) the polynucleotide substratum is multilayered.

38 3. A method according to claim 1 or claim 2 wherein the solid polymeric support comprises polystyrene, for example polystyrene configured to include microtiter wells, tubes or dipsticks.

40 4. A method according to any one of the preceding claims, further comprising the step of combining the sample with a quantity of a chaotropic agent sufficient to disrupt molecular structures in cells and to render nucleic acids available for hybridization, prior to contacting said sample with the preimmobilized capture probe in Claim 1, step (c), the chaotropic agent being for example guanidinium thiocyanate.

45 5. A method according to any one of the preceding claims wherein the tail of the capture probe is a polymer of from about 10 to about 50 nucleotides.

60 6. A method according to any one of the preceding claims, further comprising the steps of:
(a) combining, under hybridizing conditions, the sample with a labeled probe capable of hybridizing to the target nucleic acid, such that if the target nucleic acid is present in the sample, a labeled immobilized target nucleic acid is obtained in step (c) of Claim 1; or
55 (a') contacting, under hybridizing conditions, the immobilized target nucleic acid of Claim 1, step (c) with a labeled probe capable of hybridizing to the target nucleic acid, such that if the target nucleic acid is present in the sample, a labeled immobilized target nucleic acid is obtained; and
7. A method according to any one of Claims 1-5, further comprising the steps of:
   (a) washing the preimmobilized capture probe with a wash buffer appropriate to lower nonspecific binding; or
   (a') washing the immobilized target nucleic acid with a wash buffer appropriate to lower nonspecific binding;
   (b) contacting, under hybridizing conditions, the washed immobilized target nucleic acid with a labeled probe capable of hybridizing to the target nucleic acid, such that if the target nucleic acid is present in the sample, a labeled immobilized target nucleic acid is obtained in which nonspecific binding of the labeled probe is reduced; and
   (c) detecting the presence or amount of the labeled immobilized target nucleic acid.

8. A method according to claim 7 wherein:
   (a) the wash buffer comprises a solution of a tetraalkylammonium salt, selected for example from tetraethylammonium chloride, tetraethylammonium bromide, tetramethylammonium chloride and tetramethylammonium bromide, such that the first hybridized region is stabilized by the tetraalkylammonium salt; and
   (b) the wash step of claim 7 is carried out under conditions at which the first hybridized region would otherwise dissociate, thereby significantly reducing nonspecific binding while maintaining the stability of the first hybridized region.

9. A method according to any one of claims 1-3 wherein the tail of the capture probe is a polymer of from about 10 to about 30 nucleotides and wherein the hybridizing conditions under which the second hybridized region is formed are sufficient to maintain stability of the first hybridized region, further comprising the steps of:
   (a) contacting the immobilized target nucleic acid with a chaotropic solvent sufficient to destabilize either the first hybridized region or the second hybridized region, whereby a released target nucleic acid is obtained;
   (b) providing a second polynucleotide substrate affixed to a second solid polymeric support, wherein the second polynucleotide is a homopolynucleotide or is the polymer of a simple repeating nucleotide sequence, for example an alternating nucleotide sequence or a tetrancleotide sequence;
   (c) contacting, under hybridizing conditions, the second polynucleotide substrate with a second capture probe consisting essentially of a target binding region and a tail which is a polymer of 30 to about 100 nucleotides, the sequence of which is complementary to the second polynucleotide substrate, such that a third hybridized region is formed between the second capture probe tail and the second polynucleotide substrate to obtain a preimmobilized second capture probe; and
   (d) contacting the released target nucleic acid with the preimmobilized second capture probe under hybridizing conditions, such that a fourth hybridized region is formed between the target nucleotide sequence and the target binding region of the second capture probe to obtain a recaptured target nucleic acid.

10. A method according to claim 9, wherein:
    (a) the tail of the first capture probe is a polymer of from about 10 to about 20 nucleotides; or
    (b) the second polynucleotide substrate is a (dT) or (dA) homopolymer or the polymer of a simple repeating nucleotide sequence of (dT) and (dA), for example (dT)ₙ, (dA)ₙ, (dAdT)ₙ, or (dAdTdT)ₙ, where n is sufficiently large to refer to a polymer of from about 50 to about 3000 nucleotides and the first hybridized region is stabilized by a tetraalkylammonium salt;
    (c) the chaotropic solvent is GuSCN; or
    (d) the oligonucleotide sequence of the target binding region of the second capture probe is the same as the oligonucleotide sequence of the target binding region of the first capture probe; or
    (e) the oligonucleotide sequence of the target binding region of the second capture probe is different from the oligonucleotide sequence of the target binding region of the first capture probe, such that overall specificity for the target nucleic acid is enhanced.

11. A method according to claim 9 or claim 10, further comprising the steps of:
    (a) combining, under hybridizing conditions, the sample with a labeled probe capable of hybridizing to the target nucleic acid, such that if the target nucleic acid is present in the sample, a labeled
target nucleic acid is obtained; or
(a') contacting, under hybridizing conditions, the immobilized target nucleic acid with a labeled probe capable of hybridizing to the target nucleic acid, such that if the target nucleic acid is present in the sample, a labeled immobilized target nucleic acid is obtained; or
(b') combining, under hybridizing conditions, the released target nucleic acid with a labeled probe capable of hybridizing to the target nucleic acid, such that if the target nucleic acid is present in the sample, a labeled released target nucleic acid is obtained; or
(a'') contacting, under hybridizing conditions, the recaptured target nucleic acid with a labeled probe capable of hybridizing to the target nucleic acid, such that if the target nucleic acid is present in the sample, a labeled recaptured target nucleic acid is obtained; and
(b) detecting the presence or amount of the labeled recaptured target nucleic acid.

12. A method according to any one of claims 9-11 wherein the chaotropic solvent destabilizes the first hybridized region such that the first capture probe remains hybridized to the released target nucleic acid, further wherein:
(a) the second polynucleotide substratum is substantially saturated with the tail of the second capture probe, such that the tail of the first capture probe is prevented from hybridizing to the second polynucleotide substratum; or
(b) the released target nucleic acid having first capture probe bound thereto is contacted, under hybridizing conditions and prior to contact of the released target nucleic acid with the second preimmobilized capture probe, with a quantity of a soluble polynucleotide complementary to the tail of the first capture probe sufficient to hybridize to substantially all of said first capture probe tails, for an appropriate length of time such that essentially no free first capture probe tail is available to hybridize to the second polynucleotide substratum during recapture; or
(c) the preimmobilized second capture probe is contacted, under hybridizing conditions and prior to contact of the released target nucleic acid with the preimmobilized second capture probe, with a quantity of a soluble polynucleotide complementary to the second polynucleotide substratum sufficient to hybridize to any of said second polynucleotide substratum not hybridized to second capture probe tails, such that essentially no free first capture probe tail can hybridize to the second polynucleotide substratum during recapture.

13. A method according to any one of claims 9-11 wherein:
(a) the first hybridized region is stabilized relative to a mixed base sequence hybrid, by a tetraalkylammonium salt, selected for example from tetraethylammonium chloride, tetraethylammonium bromide, tetramethylammonium chloride and tetramethylammonium bromide; and
(b) the immobilized target nucleic acid is contacted with the chaotropic solvent at a temperature at which the second, mixed base sequence hybridized region between the target nucleic acid and the first capture probe is unstable yet at which the stabilized first hybridized region remains stable, such that target nucleic acid is released and the first capture probe remains hybridized to the first polynucleotide substratum.

14. A method according to any one of the preceeding claims, wherein the target nucleic acid is a bacterial nucleic acid or a viral nucleic acid.

15. A kit comprising:
(a) solid polymeric supports, each having affixed thereto a polynucleotide substratum comprising a (dT) or (dA) homopolymer or the polymer of a simple repeating nucleotide sequence of (dT) and (dA), for example (dT)ₙ, (dA)ₙ, (dAdT)ₙ or (dAdAdTdT)ₙ, where n is sufficiently large to refer to a polymer of from about 50 to about 3000 nucleotides;
(b) capture probe comprised of a target-specific oligonucleotide, the sequence of which is specific for a target nucleotide sequence, and an oligonucleotide or polynucleotide tail, comprising a polymer of from about 10 to about 50 nucleotides the sequence of which is complementary to the polynucleotide substratum; and
(c) a chaotropic agent sufficient to disrupt molecular structures in cells.

16. A kit according to claim 15, wherein:
(a) the solid polymeric supports comprise agarose beads, polystyrene microtiter wells, polystyrene tubes or polystyrene dipsticks; or
17. A kit according to claim 15 or claim 16, further comprising at least two different capture probes, the target-specific oligonucleotides of which are specific respectively for at least two different target nucleic acids, such that the kit can be used to test a sample simultaneously for the presence or at least two different target nucleic acids, and wherein the capture probes are prehybridized respectively to at least two solid polymeric supports.

18. A kit according to claim 17, further comprising a generic labeled probe capable of hybridizing to each of said different target nucleic acids.

Patentansprüche

1. Verfahren zum Isolieren oder Bestimmen der Anwesenheit oder Menge einer Ziel-Nucleinsäure in einer Probe, wobei das Verfahren von dem Typ ist, der die Verwendung von folgendem umfaßt: (i) einer immobilisierbaren Einfangszone, die einen Schwan und einen Ziel-Bindungsbereich aufweist, der eine Mischbasen-Oligonucleotidsequenz, die der Ziel-Nucleinsäuressequenz komplementär ist, und (ii) eines Substrats, das an einem festen Träger haftet, wobei der Schwan und das Substrat gemeinsam ein Affinitätspaar bilden, dadurch gekennzeichnet, daß das Verfahren die folgenden Schritte aufweist:
   (a) Zur Verfügung stellen eines Polynucleotidsubstrats, das ein (dT)- oder (dA)-Homopolymer oder das Polymer einer einfachen repetitiven Nucleotidsequenz von (dT) und (dA), beispielsweise (dT)n, (dA)n, (dAdT)n, oder (dAdAdT)n, umfaßt, wobei n hinreichend groß ist, um sich auf ein Polymer von ca. 50 bis ca. 3000 Nucleotiden, die an einem festen polymeren Träger haften, zu beziehen;
   (b) unter Hybridisierungsbedingungen In-Kontakt-Bringen des Polynucleotidsubstrats mit einer Einfangszone, die im wesentlichen aus einem Ziel-Bindungsbereich und einem Schwan besteht, der ein Oligonucleotid oder ein Polynucleotid ist, dessen Sequenz zu der des Polynucleotidsubstrats komplementär ist, so daß zwischen dem Schwan und dem Polynucleotidsubstrat ein erster hybridisierter Bereich gebildet wird, um eine vorimmobilisierte Einfangszone zu erhalten; und
   (c) In-Kontakt-Bringen der Probe mit der vorimmobilisierten Einfangszone unter Hybridisierungsbedingungen, so daß, wenn die Ziel-Nucleinsäure in der Probe anwesend ist, ein zweiter hybridisierter Bereich zwischen der Ziel-Nucleotidsequenz und dem Ziel-Bindungsbereich der Einfangszone gebildet wird, um eine immobilisierte Ziel-Nucleinsäure zu erhalten.

2. Verfahren nach Anspruch 1, wobei:
   (a) der Schwan der Einfangszone beispielsweise synthetisch oder enzymatisch mit dem 3'-Ende, dem 5'-Ende oder wenigstens einem internen Rest des Ziel-Bindungsbereichs der Einfangszone gekoppelt wird, allerdings mit der Maßgabe, daß der Ziel-Bindungsbereich fähig bleibt, den zweiten hybridisierten Bereich mit der Ziel-Nucleotidsequenz zu bilden und wobei
   (b) der Ziel-Bindungsbereich der Einfangszone ein DNA-Oligonucleotid ist und der Schwan DNA oder RNA ist; oder
   (c) der Ziel-Bindungsbereich der Einfangszone ein RNA-Oligonucleotid ist und der Schwan DNA oder RNA ist; oder
   (d) das Polynucleotidsubstrat vielschichtig ist.

3. Verfahren nach Anspruch 1 oder 2, wobei der feste polymeren Träger Polystyrol aufweist, beispielsweise Polystyrol, das ausgebildet ist, um Mikrotiter-Vertiefungen, Röhrchen oder Pipetten (dipsticks) zu umfassen.

4. Verfahren nach einem der vorhergehenden Ansprüche, das ferner den Schritt aufweist: Vereinigen der Probe mit ei n mer Nern eines chaotropen Agens, die ausreicht, um Moleküllstrukturen in Zellen zu zerstören und Nucleinsäuren zur Hybridisierung verfügbar zu machen, und zwar vor dem In-Kontakt-Bringen der Probe mit der vorimmobilisierten Einfangszone aus Anspruch 1, Schritt (c), wobei das chaotrop Agens beispielsweise Guadiniumthiocyanat ist.
5. Verfahren nach einem der vorhergehenden Ansprüche, wobei der Schwanz der Einfangsonde ein Polymer von ca. 10 bis ca. 50 Nucleotiden ist.

6. Verfahren nach einem der vorhergehenden Ansprüche, das ferner die folgenden Schritte aufweist:
   (a) unter Hybridisierungsbedingungen Vereinigen der Probe mit einer markierten Sonde, die fähig ist, an der Ziel-Nucleinsäure zu hybridisieren, so daß, wenn die Ziel-Nucleinsäure in der Probe anwesend ist, eine markierte immobilisierte Ziel-Nucleinsäure in Schritt (c) von Anspruch 1 erhalten wird; oder
   (a') unter Hybridisierungsbedingungen In-Kontakt-Bringen der immobilisierten Ziel-Nucleinsäure von Anspruch 1, Schritt (c), mit einer markierten Sonde, die fähig ist, an der Ziel-Nucleinsäure zu hybridisieren, so daß, wenn die Ziel-Nucleinsäure in der Probe anwesend ist, eine markierte immobilisierte Ziel-Nucleinsäure erhalten wird; und
   (b) Nachweisen der Anwesenheit oder der Menge der markierten immobilisierten Ziel-Nucleinsäure.

7. Verfahren nach einem der Ansprüche 1-5, das ferner die folgenden Schritte aufweist:
   (a) Waschen der vorimmobilisierten Einfangsonde mit einer Waschpufferlösung, die geeignet ist, nichtspezifisches Binden zu verringern; oder
   (a') Waschen der immobilisierten Ziel-Nucleinsäure mit einer Waschpufferlösung, die geeignet ist, nichtspezifisches Binden zu verringern;
   (b) unter Hybridisierungsbedingungen In-Kontakt-Bringen der gewaschenen immobilisierten Ziel-Nucleinsäure mit einer markierten Sonde, die fähig ist, an der Ziel-Nucleinsäure zu hybridisieren, so daß, wenn die Ziel-Nucleinsäure in der Probe anwesend ist, eine markierte immobilisierte Ziel-Nucleinsäure erhalten wird, bei der nichtspezifisches Binden der markierten Sonde verringert ist; und
   (c) Nachweisen der Anwesenheit oder der Menge der markierten immobilisierten Ziel-Nucleinsäure.

8. Verfahren nach Anspruch 7, wobei:
   (a) die Waschpufferlösung eine Lösung eines Tetraalkylammoniumsalzes aufweist, das beispielsweise aus Tetraethylammoniumchlorid, Tetraethylammoniumbromid, Tetramethylammoniumchlorid und Tetramethylammoniumbromid, so daß der erste hybridisierte Bereich durch das Tetraalkylammoniumsalz stabilisiert wird; und
   (b) der Wasch-Schritt von Anspruch 7 unter Bedingungen durchgeführt wird, bei denen der erste hybridisierte Bereich sonst dissoziiert würde, um dadurch nichtspezifisches Binden signifikant zu verringern, während gleichzeitig die Stabilität des ersten hybridisierten Bereichs beibehalten wird.

9. Verfahren nach einem der Ansprüche 1-3, wobei der Schwanz der Einfangsonde ein Polymer von ca. 10 bis ca. 30 Nucleotiden ist und wobei die Hybridisierungsbedingungen, unter denen der zweite hybridisierte Bereich gebildet wird, ausreichend sind, um die Stabilität des ersten hybridisierten Bereichs beizubehalten, wobei das Verfahren ferner die folgenden Schritte aufweist:
   (a) In-Kontakt-Bringen der immobilisierten Ziel-Nucleinsäure mit einem chaotropen Lösungsmittel, das ausreichend, um entweder den ersten hybridisierten Bereich oder den zweiten hybridisierten Bereich zu destabilisieren, wodurch eine freigesetzte Ziel-Nucleinsäure erhalten wird;
   (b) Vorsehen eines zweiten Polynucleotidsubstrats, das an einem zweiten festen polymeren Träger haftet, wobei das zweite Polynucleotid ein Homopolynucleotid oder das Polymer einer einfachen repetitiven Nucleotidsequenz, beispielsweise einer alternierenden Nucleotidsequenz oder einer Tetranucleotidsequenz, ist;
   (c) unter Hybridisierungsbedingungen In-Kontakt-Bringen des zweiten Polynucleotidsubstrats mit einer zweiten Einfangsonde, die im wesentlichen aus einem Ziel-Bindungsbereich und einem Schwanz besteht, der ein Polymer von 30 bis ca. 100 Nucleotiden ist, deren Sequenz zu dem zweiten Polynucleotidsubstrat komplementär ist, so daß der zweite hybridisierte Bereich zwischen dem zweiten Einfangsonden-Schwanz und dem zweiten Polynucleotidsubstrat gebildet wird, um eine vorimmobilisierte zweite Einfangsonde zu erhalten; und
   (d) In-Kontakt-Bringen der freigesetzten Ziel-Nucleinsäure mit der vorimmobilisierten zweiten Einfangsonde unter Hybridisierungsbedingungen, so daß ein viertes hybridisierter Bereich zwischen der Ziel-Nucleotidsequenz und dem Ziel-Bindungsbereich der zweiten Einfangsonde gebildet wird, um eine wiedereingefangene Ziel-Nucleinsäure zu erhalten.

10. Verfahren nach Anspruch 9, wobei:
(a) der Schwanz der ersten Einfangsonde ein Polymer von ca. 10 bis ca. 20 Nucleotiden ist; oder
(b) das zweite Polynucleotidsubstrat ein (dT)- oder (dA)-Homopolymer oder das Polymer einer einfachen repetitiven Nucleotidsequenz von (dT) n oder (dA) m, beispielsweise (dT) n, (dA) m, (dAdT) n oder (dAdTdT) n, ist, wobei n ausreichend groß ist, um sich auf ein Polymer von ca. 50 bis ca. 3000 Nucleotiden zu beziehen, und der erste hybridisierte Bereich durch ein Tetraalkylammoniumsalz stabilisiert wird;
(c) das chaotrope Lösungsmittel GuSCN ist; oder
die Oligonucleotidsequenz des Ziel-Bindungsbereichs der zweiten Einfangsonde gleiche wie die Oligonucleotidsequenz des Ziel-Bindungsbereichs der ersten Einfangsonde ist; oder
e die Oligonucleotidsequenz des Ziel-Bindungsbereichs der zweiten Einfangsonde von der Oligonucleotidsequenz des Ziel-Bindungsbereichs der ersten Einfangsonde verschieden ist, so daß die Gesamtspesifität für die Ziel-Nucleinsäure gesteigert ist.

11. Verfahren nach Anspruch 9 oder Anspruch 10, das ferner die folgenden Schritte aufweist:
(a) unter Hybridisierungsbedingungen Vereinigen der Probe mit einer markierten Probe, die fähig ist, an der Ziel-Nucleinsäure zu hybridisieren, so daß, wenn die Ziel-Nucleinsäure in der Probe anwesend ist, eine markierte Ziel-Nucleinsäure erhalten wird; oder
(a') unter Hybridisierungsbedingungen In-Kontakt-Bringen der immobilisierten Ziel-Nucleinsäure mit einer markierten Sonde, die fähig ist, an der Ziel-Nucleinsäure zu hybridisieren, so daß, wenn die Ziel-Nucleinsäure in der Probe anwesend ist, eine markierte immobilisierte Ziel-Nucleinsäure erhalten wird;
oder
(a'') unter Hybridisierungsbedingungen Vereinigen der freigesetzten Ziel-Nucleinsäure mit einer markierten Sonde, die fähig ist, an der Ziel-Nucleinsäure zu hybridisieren, so daß, wenn die Ziel-Nucleinsäure in der Probe anwesend ist, eine markierte freigesetzte Ziel-Nucleinsäure erhalten wird; oder
oder
(a''') unter Hybridisierungsbedingungen In-Kontakt-Bringen der wiedereingefangenen Ziel-Nucleinsäure mit einer markierten Sonde, die fähig ist, an der Ziel-Nucleinsäure zu hybridisieren, so daß, wenn die Ziel-Nucleinsäure in der Probe anwesend ist, eine markierte wiedereingefangene Ziel-Nucleinsäure erhalten wird; und
(b) Nachweisen der Anwesenheit oder der Menge der markierten wiedereingefangenen Ziel-Nucleinsäure.

12. Verfahren nach einem der Ansprüche 9-11, wobei das chaotrope Lösungsmittel den ersten hybridisierten Bereich destabilisiert, so daß die erste Einfangsonde an der freigesetzten Ziel-Nucleinsäure hybridisiert bleibt, und wobei ferner:
(a) das zweite Polynucleotidsubstrat mit dem Schwanz der zweiten Einfangsonde im wesentlichen gesättigt wird, so daß der Schwanz der ersten Einfangsonde an einer Hybridisierung an dem zweiten Polynucleotidsubstrat gehindert ist; oder
(b) die freigesetzte Ziel-Nucleinsäure, an die die erste Einfangsonde gebunden war, unter Hybridisierungsbedingungen und vor dem Kontakt der freigesetzten Ziel-Nucleinsäure mit der zweiten vorimmobilisierten Einfangsonde mit einer Menge eines löslichen Polynucleotids, das zu dem Schwanz der ersten Einfangsonde komplementär ist, in Kontakt gebracht wird und die Menge ausreicht, um im wesentlichen sämtliche Schwänze der ersten Einfangsonde zu hybridisieren, und zwar für eine ausreichende Zeit, so daß im wesentlichen kein freier erster Einfangsonden-Schwanz verfügbar ist, um während des Wiedereingangs an dem zweiten Polynucleotidsubstrat zu hybridisieren; oder
c) die vorimmobilisierte zweite Einfangsonde unter Hybridisierungsbedingungen und vor dem Kontakt der freigesetzten Ziel-Nucleinsäure mit der vorimmobilisierten zweiten Einfangsonde mit einer Menge eines löslichen Polynucleotids in Kontakt gebracht wird, das zu dem zweiten Polynucleotidsubstrat komplementär ist, wobei die Menge ausreicht, um an jedem Teil des zweiten Polynucleotidsubstrats, der nicht an zweite Einfangsonden-Schwänze hybridisiert ist, zu hybridisieren, so daß im wesentlichen kein freier erster Einfangsonden-Schwanz an dem zweiten Polynucleotidsubstrat während des Wiedereingangs hybridisiert kann.

13. Verfahren nach einem der Ansprüche 9-11, wobei:
(a) der erste hybridisierte Bereich relativ zu einem Hybrid mit Mischbasensequenz stabilisiert wird durch ein Tetraalkylammoniumsalz, das beispielsweise ausgewählt ist aus Tetraethylammoniumchlorid, Tetraethylammoniumbromid, Tetramethylammoniumchlorid und Tetramethylammoniumbromid; und

15. Set, das folgendes aufweist:
   (a) feste polymere Träger, an denen jeweils ein Polynucleotidsubstrat haftet, das ein (dT)- oder (dA)-Homopolymer oder das Polymer einer einfachen repetitiven Nucleotidsequenz von (dT) und (dA), beispielsweise \( (dT)_n(dA)_m \), \( (dAdT)_n \) oder \( (dAdAdTdT)_n \) umfaßt, wobei \( n \) ausreichend groß ist, um sich auf ein Polymer von ca. 50 bis ca. 3000 Nucleotiden zu beziehen;
   (b) eine Einfangsonde, die aus einem Ziel-spezifischen Oligonucleotid, dessen Sequenz für eine Ziel-Nucleotidsequenz spezifisch ist, und einem Oligonucleotid- oder Polynucleotid-Schwanze besteht, der ein Polymer von ca. 10 bis ca. 50 Nucleotiden aufweist, deren Sequenz zu dem Polynucleotidsubstrat komplementär ist; und
   (c) ein chaotropes Agens, das ausreicht, um Moleküllstrukturen in Zellen zu zerstören.

16. Set nach Anspruch 15, wobei:
   (a) die festen polymeren Träger Agarose-Kügelchen, Polystyrol-Mikrotiter-Vertiefungen, Polystyrol-Röhren oder Polystyrol-Pipetten umfassen; oder
   (b) der Schwanze der Einfangsonde ein Polymer von ca. 10 bis ca. 50 Nucleotiden ist; oder
   (c) die Einfangsonde an dem Polynucleotidsubstrat vorhybridisiert ist; oder
   (d) das Set ferner aufweist: eine Waschpufferlösung, eine markierte Oligonucleotid-Sonde, die fähig ist, an eine Ziel-Nucleinsäure zu binden, Mittel zum Nachweisen der markierten Oligonucleotid-Sonde, eine oder mehrere positive Kontrollproben, eine oder mehrere negative Kontrollproben, Elutionspuffer zum reversiblen Zieleinfang oder Verstärkungs- oder Klonierungs-Reagenzien.

17. Set nach Anspruch 15 oder Anspruch 16, das ferner wenigstens zwei verschiedene Einfangsonden aufweist, deren Ziel-spezifische Oligonucleotide jeweils für wenigstens zwei verschiedene Ziel-Nucleinsäuren spezifisch sind, so daß das Set verwendbar ist, um eine Probe gleichzeitig auf die Anwesenheit von wenigstens zwei verschiedenen Ziel-Nucleinsäuren zu testen, und wobei die Einfangsonden jeweils an wenigstens zwei feste polymere Träger vorhybridisiert sind.

18. Set nach Anspruch 17, das ferner eine generisch markierte Sonde aufweist, die fähig ist, an jeder der genannten verschiedenen Ziel-Nucleinsäuren zu hybridisieren.

Revendications

1. Une méthode pour isoler ou déterminer la présence, ou la quantité, d'un acide nucléique cible, dans un échantillon, la méthode étant du type qui implique l'utilisation (i) d'une sonde de capture immobilisable comprenant une queue et une région de liaison à une cible, qui est une séquence d'oligonucléotides renfermant des bases mélangées, complémentaire à la séquence de l'acide nucléique cible et (ii) d'un substrat qui est fixé à un support solide, la queue et le substrat formant ensemble une paire d'affinité, caractérisée en ce que ladite méthode comprend les étapes de:
   (a) fournir un substrat de polynucleotidocompsrent un homopolymère (dT) ou (dA) ou le polymère d'une séquence de nucléotides répétitive simple de (dT) et de (dA), par exemple \( (dT)_n \), \( (dAdT)_n \), dans lesquelles \( n \) est suffisamment grand pour se rapporter à un polymère de environ 50 à environ 3000 nucléotides, fixé à un support polymère solide;
   (b) mettre en contact, dans des conditions propices à l'hybridation, le substrat de polynucleotidocompsrent une sonde de capture consistant essentiellement en une région de liaison à une cible et en une queue qui est un oligonucléotide ou un polynucléotide, dont la séquence est complémentaire au substrat de polynucleotidocompsrent, de sorte que une première région hybridée est formée entre la queue et le substrat de polynucleotidocompsrent, pour obtenir une sonde de capture préimmobilisée; et
   (c) mettre en contact l'échantillon avec la sonde de capture préimmobilisée, dans des conditions propices à l'hybridation, de sorte que si l'acide nucléique cible est présent dans l'échantillon, une
2. Une méthode, conformément à la revendication 1, dans laquelle:
   (a) la queue de la sonde de capture est reliée, par exemple, synthétiquement ou enzymatiquement reliée, à l'extrémité 3', à l'extrémité 5' ou, au moins, à un résidu interne de la région de liaison à la cible, à condition, cependant, que la région de liaison à la cible reste capable de former la seconde région hybridée avec la séquence de nucléotides cible; et dans laquelle
   (b) la région de liaison à la cible de la sonde de capture est un oligonucléotide d'ADN et la queue est de l'ADN ou de l'ARN; ou
   (c) la région de liaison à la cible de la sonde de capture est un oligonucléotide d'ARN et la queue est de l'ADN ou de l'ARN; ou
   (d) le substrat de polynucléotides est multicouche.

3. Une méthode, conformément à la revendication 1 ou à la revendication 2, dans laquelle le support polymère solide comprend du polystyrène, par exemple du polystyrène configuré de façon à comprendre des puits de microtitrage, des tubes ou des jauge.

4. Une méthode, conformément à l'une quelconque des revendications précédentes, comprenant, en outre, les étapes de combiner l'échantillon avec une quantité d'un agent chaotropique suffisante pour rompre les structures moléculaires, dans les cellules et rendre les acides nucléiques disponibles pour une hybridation, avant de mettre en contact ledit échantillon avec la sonde de capture préimmobilisée de la revendication 1, étape (c), l'agent chaotropique étant, par exemple, du thiocyanate de guanidine.

5. Une méthode, conformément à l'une quelconque des revendications précédentes, dans laquelle la queue de la sonde de capture est un polymère de environ 10 à environ 50 nucléotides.

6. Une méthode, conformément à l'une quelconque des revendications précédentes, comprenant, en outre, les étapes de:
   (a) combiner, dans des conditions propices à l'hybridation, l'échantillon avec une sonde marquée capable de s'hybrider à l'acide nucléique cible, de sorte que si l'acide nucléique cible est présent dans l'échantillon, un acide nucléique cible marqué, immobilisé, est obtenu à l'étape (c) de la revendication 1; ou
   (a') mettre en contact, dans des conditions propices à l'hybridation, l'acide nucléique cible immobilisé de la revendication 1, étape (c), avec une sonde marquée capable de s'hybrider à l'acide nucléique cible, de sorte que si l'acide nucléique cible est présent dans l'échantillon, un acide nucléique cible marqué, immobilisé, est obtenu; et
   (b) détecter la présence ou la quantité de l'acide nucléique cible marqué, immobilisé.

7. Une méthode, conformément à l'une quelconque des revendications 1-5, comprenant, en outre, les étapes de:
   (a) laver la sonde de capture préimmobilisée avec un tampon de lavage approprié pour diminuer la liaison non spécifique; ou
   (a') laver l'acide nucléique cible immobilisé avec un tampon de lavage approprié pour diminuer la liaison non spécifique;
   (b) mettre en contact, dans des conditions propices à l'hybridation, l'acide nucléique cible lavé, immobilisé avec une sonde marquée capable de s'hybrider à l'acide nucléique cible, de sorte que si l'acide nucléique cible est présent dans l'échantillon, un acide nucléique cible marqué, immobilisé, est obtenu, dans lequel la liaison non spécifique de la sonde marquée est réduite; et
   (c) détecter la présence ou la quantité de l'acide nucléique cible marqué, immobilisé.

8. Une méthode, conformément à la revendication 7, dans laquelle:
   (a) le tampon de lavage comprend une solution d'un sel de tétra-alkylammonium, sélectionné, par exemple, parmi chlorure de tétra-éthylammonium, bromure de tétra-éthylammonium, chlorure de tétra-méthylammonium et bromure de tétra-méthylammonium, de sorte que la première région hybrédée est stabilisée par le sel de tétra-alkylammonium; et
   (b) l'étape de lavage de la revendication 7 est mise en œuvre dans des conditions dans lesquelles la première région hybrédée se dissocierait, autrement, réduisant, de ce fait, significativement la

34
liaison non spécifique tout en maintenant la stabilité de la première région hybridée.

9. Une méthode, conformément à l'une quelconque des revendications 1-3, dans laquelle la queue de la sonde de capture est un polymère de environ 10 à environ 30 nucléotides et dans laquelle les conditions propices à l'hybridation dans lesquelles la seconde région hybridée est formée sont suffisantes pour maintenir la stabilité de la première région hybridée, comprenant, en outre, les étapes de:
(a) mettre en contact l'acide nucléique cible immobilisé avec un solvant chaotropique suffisant pour destabiliser soit la première région hybridée, soit la seconde région hybridée, grâce à quoi un acide nucléique cible libéré est obtenu;
(b) fournir un second substrat de polynucléotides fixé à un second support polymère solide, dans lequel le second polynucléotide est un homopolynucléotide ou est le polymère d'une séquence de nucléotides répétitive simple, par exemple une séquence de nucléotides alternés ou une séquence de tétranucléotides;
(c) mettre en contact, dans des conditions propices à l'hybridation, le second substrat de polynucléotides avec une seconde sonde de capture consistant essentiellement en une région de liaison à une cible et en une queue qui est un polymère de 30 à environ 100 nucléotides, dont la séquence est complémentaire au second substrat de polynucléotides, de sorte qu'une troisième région hybridée est formée entre la queue de la seconde sonde de capture et le second substrat de polynucléotides, pour obtenir une seconde sonde de capture préimmobilisée; et
(d) mettre en contact l'acide nucléique cible libéré avec la seconde sonde de capture préimmobilisée, dans des conditions propices à l'hybridation, de sorte qu'une quatrième région hybridée est formée entre la séquence de nucléotides cible et la région de liaison à la cible de la seconde sonde de capture, pour obtenir un acide nucléique cible recapturé.

10. Une méthode, conformément à la revendication 9, dans laquelle:
(a) la queue de la première sonde de capture est un polymère de environ 10 à environ 20 nucléotides; ou
(b) le second substrat de polynucléotides est un homopolymère (dT) ou (dA) ou le polymère d'une séquence de nucléotides répétitive simple de (dT) et de (dA), par exemple (dT)_n (dA)_m (dAdT)_n ou (dAdAtdT)_m dans lesquelles n est suffisamment grand pour se rapporter à un polymère de environ 50 à environ 3000 nucléotides et la première région hybridée est stabilisée par un sel de tétraalkylammonium;
(c) le solvant chaotropique est le GuSCN; ou
(d) la séquence d'oligonucléotides de la région de liaison à la cible de la seconde sonde de capture est la même que la séquence d'oligonucléotides de la région de liaison à la cible de la première sonde de capture; ou
(e) la séquence d'oligonucléotides de la région de liaison à la cible de la seconde sonde de capture est différente de la séquence d'oligonucléotides de la région de liaison à la cible de la première sonde de capture, de sorte que la spécificité globale, pour l'acide nucléique cible, est augmentée.

11. Une méthode, conformément à la revendication 9 ou à la revendication 10, comprenant, en outre, les étapes de:
(a) combiner, dans des conditions propices à l'hybridation, l'échantillon avec une sonde marquée capable de s'hybrider à l'acide nucléique cible, de sorte que si l'acide nucléique cible est présent dans l'échantillon, un acide nucléique cible marqué est obtenu; ou
(a') mettre en contact, dans des conditions propices à l'hybridation, l'acide nucléique cible immobilisé avec une sonde marquée capable de s'hybrider à l'acide nucléique cible, de sorte que si l'acide nucléique cible est présent dans l'échantillon, un acide nucléique cible, marqué, immobilisé, est obtenu; ou
(a'') combiner, dans des conditions propices à l’hybridation, l’acide nucléique cible libéré avec une sonde marquée capable de s’hybrider à l’acide nucléique cible, de sorte que si l’acide nucléique cible est présent dans l’échantillon, un acide nucléique cible marqué, libéré, est obtenu; ou
(a'''') mettre en contact, dans des conditions propices à l’hybridation, l’acide nucléique cible recapturé avec une sonde marquée capable de s’hybrider à l’acide nucléique cible, de sorte que si l’acide nucléique cible est présent dans l’échantillon, un acide nucléique cible marqué, recapturé, est obtenu; et
(b) détecter la présence ou la quantité d’acide nucléique cible marqué, recapturé.
12. Une méthode, conformément à l'une quelconque des revendications 9-11, dans laquelle le solvant chaotropique déstabilise la première région hybridée, de sorte que la première sonde de capture reste hybridée à l'acide nucléique cible libéré, dans laquelle, en outre:
(a) le second substrat de polynucléotides est essentiellement saturé avec la queue de la seconde sonde de capture, de sorte que la queue de la première sonde de capture est préservée de l'hybridation au second substrat de polynucléotides; ou
(b) l'acide nucléique cible libéré, auquel est lié une première sonde de capture, est mis en contact, dans des conditions propices à l'hybridation, et avant la mise en contact de l'acide nucléique cible libéré avec la seconde sonde de capture prémobilisée, avec une quantité d'un polynucléotide soluble, complémentaire à la queue de la première sonde de capture, suffisante pour s'hybrider à essentiellement la totalité des dés queues des premières sondes de capture, pendant une durée appropriée, de sorte que essentiellement aucune queue des premières sondes de capture libre n'est disponible pour s'hybrider au second substrat de polynucléotides, lors de la recapture; ou
(c) la seconde sonde de capture prémobilisée est mise en contact, dans des conditions propices à l'hybridation, et avant la mise en contact de l'acide nucléique cible libéré avec la seconde sonde de capture prémobilisée, avec une quantité d'un polynucléotide soluble, complémentaire au second substrat de polynucléotides, suffisante pour s'hybrider à l'une quelconque desdits seconds substrats de polynucléotides non hybridés aux queues des secondes sondes de capture, de sorte que essentiellement aucune queue des premières sondes de capture libre ne peut s’hybrider au second substrat de polynucléotides, lors de la recapture.

13. Une méthode, conformément à l’une quelconque des revendications 9-11, dans laquelle:
(a) la première région hybridée est stabilisée en ce qui concerne un hybride de séquences renfermant des bases mélangées, par un sel de tétra-alkylammonium, sélectionné, par exemple, parmi chlorure de tétra-éthylammonium, bromure de tétra-éthylammonium, chlorure de tétra-méthylammonium et bromure de tétra-méthylammonium; et
(b) l'acide nucléique cible immobilisé est mis en contact avec le solvant chaotropique, à une température à laquelle la seconde région hybridée de la séquence renfermant des bases mélangées, entre l'acide nucléique cible et la première sonde de capture est instable et, encore, à laquelle la première région hybridée stabilisée reste stable, de sorte que l'acide nucléique cible est libéré et que la première sonde de capture reste hybridée au premier substrat de polynucléotides.

14. Une méthode, conformément à l’une quelconque des revendications précédentes, dans laquelle l'acide nucléique cible est un acide nucléique bactérien ou un acide nucléique viral.

15. Un nécessaire comprenant:
(a) des supports polymères solides, sur chacun d'entre eux étant fixé un substrat de polynucléotides comprenant un homopolymère (dT) ou (dA) ou le polymère d'une séquence de nucléotides répétitive simple de (dT) et de (dA), par exemple (dT)ₙ (dA)ₙ, (dAdT)ₙ ou (dAdAdTdT)ₙ, dans lesquelles n est suffisant grand pour se rapporter à un polymère de environ 50 à environ 3000 nucléotides;
(b) une sonde de capture composée d’un oligonucléotide cible-spécifique, dont la séquence est spécifique d’une séquence de nucléotides cible et d’une queue d’oligonucléotides ou de polynucléotides, comprenant un polymère de environ 10 à environ 50 nucléotides, dont la séquence est complémentaire au substrat de polynucléotides; et
(c) un agent chaotropique suffisant pour rompre les structures moléculaires, dans les cellules.

16. Un nécessaire, conformément à la revendication 15, dans lequel:
(a) les supports polymères solides comprennent des billes d'agarose, des puits de microtirage de polystyrène, des tubes de polystyrène ou des jauges de polystyrène; ou
(b) la queue de la sonde de capture est un polymère de environ 10 à environ 50 nucléotides; ou
(c) la sonde de capture est préhybrédée au substrat de polynucléotides; ou
(d) comprenant, en outre, un tampon de lavage, une sonde d'oligonucléotides marquée capable de se lier à un acide nucléique cible, un moyen pour détecter la sonde d'oligonucléotides marquée, un ou plusieurs échantillons de contrôle positifs, un ou plusieurs échantillons de contrôle négatifs, des tampons d'éluion pour une capture de la cible réversible, ou des réactifs d'amplification ou de clonage.
17. Un nécessaire, conformément à la revendication 15 ou à la revendication 16, comprenant, en outre, au moins deux sondes de capture différentes, dont les oligonucléotides cible-spécifiques sont spécifiques, respectivement, de au moins deux acides nucléiques cibles différents, de sorte que le nécessaire peut être utilisé pour tester un échantillon simultanément pour la présence de au moins deux acides nucléiques cibles différents et dans lequel les sondes de capture sont préhybridées, respectivement, à au moins deux supports polymères solides.

18. Un nécessaire, conformément à la revendication 17, comprenant, en outre, une sonde marquée générique, capable de s'hybrider à chacun desdits acides nucléiques cibles différents.
FIGURE 1
FIGURE 3
Sequences of Oligonucleotide Probes

<table>
<thead>
<tr>
<th>Probe</th>
<th>Sequence (5' → 3')</th>
</tr>
</thead>
<tbody>
<tr>
<td>576</td>
<td>XXX XXX XXX XXX XXX XXX XXX XXX XXX XXX</td>
</tr>
<tr>
<td>676</td>
<td>TCA ATT GCT GCG GTT ATT AAC CAC AAC ACC TTC CT</td>
</tr>
<tr>
<td>732</td>
<td>TCC AAC TGT TGT CCT CTT GTG TAG GGC AGA TTA AC</td>
</tr>
<tr>
<td>888</td>
<td>AAA AAA AAA AAA AAA TGT GTT AAG CAG GAG TAT AGA GTA TTA GCA GTC GT</td>
</tr>
</tbody>
</table>

X = any of the four nucleotides